• Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis.
    • Yang Y, Yang X, Li H, Tong X, Zhu X.
    • J Obstet Gynaecol. 2023 Dec;43(1):2151883. doi: 10.1080/01443615.2022.2151883. Epub 2022 Dec 9.
    • Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
    • Li Y.
    • J Obstet Gynaecol. 2023 Dec;43(1):2171282. doi: 10.1080/01443615.2023.2171282.
    • Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
    • Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinier S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I.
    • Eur J Cancer. 2022 Dec 10 [2023 Mar];181:42-52. doi: 10.1016/j.ejca.2022.11.029. Epub ahead of print.

    Related:

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 10.)

    • Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    • Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC.
    • Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282. Epub ahead of print.

    Related:

    •• Identifier: NCT02855697: Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (MOLTO). (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    • PARP inhibitor-related hemorrhages:What does the real-world study say?
    • Wang S, Guo M, Fan P, Jin Z.
    • Front Oncol. 2023 Feb 14;13:1070343. doi: 10.3389/fonc.2023.1070343.
    • Long-term Data for Niraparib Support Continued Use of PARP Inhibitors in HRD+ Ovarian Cancer.
    • Roque DR, Scott R.
    • OncLive. 2023 Feb 14.
    • Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.
    • Musacchio L, Boccia S, Marchetti C, Minucci A, Camarda F, Cassani C, Ventriglia J, Salutari V, Ghizzoni V, Giudice E, Perri MT, Carbone MV, Ricci C, Pignata S, Fagotti A, Scambia G, Lorusso D.
    • Int J Gynecol Cancer. 2023 Feb 9:ijgc-2022-003903. doi: 10.1136/ijgc-2022-003903. Epub ahead of print.
    • Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
    • Perez-Fidalgo JA, Guerra E, García Y, Iglesias M, Hernández-Sosa M, Estevez-García P, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A.
    • Int J Gynecol Cancer. 2023 Feb 9:ijgc-2022-004028. doi: 10.1136/ijgc-2022-004028. Epub ahead of print.
    • Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer.
    • Huang Y, Liu C, You L, Li X, Chen G, Fan J.
    • J Cell Mol Med. 2023 Feb 8. doi: 10.1111/jcmm.17683. Epub ahead of print.
    • Management of patients with advanced epithelial ovarian cancer: a European survey.
    • Jochum F, Angeles MA, Balaya V, Drouin L, Nikolova T, Mathevet P, Lécuru F, Azais H, Betrian S, Bolze PA, Dabi Y, Kerbage Y, Sanson C, Zaccarini F, Guyon F, Akladios C, Hsu A, Bendifallah S, Deluche E, Guani B.
    • Arch Gynecol Obstet. 2023 Feb 3. doi: 10.1007/s00404-023-06948-3. Epub ahead of print.
    • Homologous Recombination Deficiency in Ovarian Cancer: From the Biological Rationale to Current Diagnostic Approaches.
    • Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, Malapelle U, Biffi S.>
    • J Pers Med. 2023 Feb 2;13(2):284. doi: 10.3390/jpm13020284.
    • Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
    • Bourien H, Lefevre LB, Mouret-Reynier MA, Asselain B, Lucas B, Gavoille C, Cornila C, Gavoille L, Colomba E, Patsouris A, Fabbro M, Chakiba C, Toussaint P, Simon H, Berton D, Garbay D, Tixidre CG, Coeffic D, Morvan A, Collard O, DE LA Motte Rouge T.
    • Anticancer Res. 2023 Feb;43(2):653-662. doi: 10.21873/anticanres.16202.
    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
    • Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ.
    • Oncologist. 2023 Jan 30:oyac275. doi: 10.1093/oncolo/oyac275. Epub ahead of print.

    Related:

    •• Identifier: NCT01033123: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    •• Identifier: NCT01033292: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
    • Heitz F, Ataseven B, Staniczok C, Denkert C, Rhiem K, Hahnen E, Heikaus S, Moubarak M, Welz J, Dagres T, Vrentas V, Bommert M, Schneider S, Concin N, Harter P.
    • Cancers (Basel). 2023 Jan 29;15(3):818. doi: 10.3390/cancers15030818.
    • PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
    • Chelariu-Raicu A, Trillsch F, Burges A, Czogalla B, Hester A, Wuerstlein R, Harbeck N, Mahner S.
    • Int J Gynecol Cancer. 2023 Jan 27:ijgc-2022-003990. doi: 10.1136/ijgc-2022-003990. Epub ahead of print.
    • Review
    • Shedding light on PARP inhibitor response through functional imaging.
    • Liu YL, Zamarin D.
    • Clin Cancer Res. 2023 Jan 26:CCR-22-3711. doi: 10.1158/1078-0432.CCR-22-3711. Epub ahead of print.
    • Commentary

    Related:

    •• Original research:

    [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study.

    • The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 24. doi: 10.1080/14737167.2023.2169136. Epub ahead of print.
    • Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.
    • Pan YE, Hood A, Ahmad H, Altwerger G.
    • Ann Pharmacother. 2023 Jan 18:10600280221149136. doi: 10.1177/10600280221149136. Epub ahead of print.
    • Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer.
    • Flaherty C, Guntupalli S.
    • OncLive. 2023 Jan 17.
    • Dr. Alldredge on Symptom Management in Ovarian Cancer During PARP Inhibitor Treatment.
    • Alldredge J.
    • OncLive. OncLive TV. 2023 Jan 17.
    • Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
    • Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M.
    • Drugs Real World Outcomes. 2023 Jan 11. doi: 10.1007/s40801-022-00349-9. Epub ahead of print.
    • Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.
    • Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevrier M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M.
    • Int J Gynecol Cancer. 2023 Jan 11:ijgc-2022-003993. doi: 10.1136/ijgc-2022-003993. Epub ahead of print.
    • A Glance at Molecular Advances in Cancer Genetics: A Baffling Puzzle Still to Be Solved.
    • Ghiorzo P, Bruno W.
    • Int J Mol Sci. 2023 Jan 11;24(2):1394. doi: 10.3390/ijms24021394.
    • An international, multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes.
    • Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim DK, Lim S, Martin E, FRENEL JS, Bocquet F, Kubelac P, Achimas-Cadariu P, Vlad C, Chevrier M, Rouzier R, Carton M, Savva-Bordalo J, Magalhães M, Borges M, Wolf A, Becker S, Niklas N, Guergova-Kuras M, Hall G.
    • Front Oncol. 2023 Jan 9;12:1114435. doi: 10.3389/fonc.2023.1114435.
    • Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS.
    • Acs M, Gerken M, Schmitt V, Piso P, Alfred Königsrainer A, Baransi S, Yurttas C, Häusler S, Horvath P.
    • Cancers (Basel). 2023 Jan 7;15(2):405. doi: 10.3390/cancers15020405.
    • Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases.
    • Ghirardi V, Fagotti A, Ansaloni L, Valle M, Roviello F, Sorrentino L, Accarpio F, Baiocchi G, Piccini L, De Simone M, Coccolini F, Visaloco M, Bacchetti S, Scambia G, Marrelli D.
    • Cancers (Basel). 2023 Jan 7;15(2):407. doi: 10.3390/cancers15020407.
    • Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    • Wu Y, Xu S, Cheng S, Yang J, Wang Y.
    • J Ovarian Res. 2023 Jan 7;16(1):6. doi: 10.1186/s13048-023-01094-5.
    • Targeting the DNA damage response for cancer therapy.
    • Curtin NJ.
    • Biochem Soc Trans. 2023 Jan 6:BST20220681. doi: 10.1042/BST20220681. Epub ahead of print.
    • Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary.
    • Penn CA, Alvarez RD.
    • JCO Oncol Pract. 2023 Jan 5:OP2200461. doi: 10.1200/OP.22.00461. Epub ahead of print.
    • Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China.
    • Nie J, Wu H, Sun L, Ding Y, Luan Y, Wu J.
    • Front Pharmacol. 2023 Jan 4;13:987337. doi: 10.3389/fphar.2022.987337.
    • Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
    • Wang DF, Shi XW, Zhang C, Zhang J, Liu H, Huang JM, Zhang GN, Wen QL.
    • Gynecol Oncol. 2023 Jan 4;170:25-31. doi: 10.1016/j.ygyno.2022.12.014. Epub ahead of print.
    • Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
    • Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S.
    • Clin Cancer Res. 2023 Jan 3:CCR-22-2032. doi: 10.1158/1078-0432.CCR-22-2032. Epub ahead of print.

    Related:

    •• Identifier: NCT03038100: A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050). (ClinicalTrials.gov . Accessed 2023 Jan 3.)

    • Treatment Complexities Continue to Mount in Gynecologic Cancers.
    • Lovely B.
    • OncLive. OncologyLive. 2023 Jan 3;23(24):35.
    • Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    • Takamatsu S, Yoshihara K, Baba T, Shimada M, Yoshida H, Kajiyama H, Oda K, Mandai M, Okamoto A, Enomoto T, Matsumura N.
    • Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122-9. Epub ahead of print.
    • Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer.
    • Jang J, Kim Y, Kim JH, Cho SM, Lee KA.
    • Ann Lab Med. 2023 Jan 1;43(1):73-81. doi: 10.3343/alm.2023.43.1.73.

    Related:

    Commentary:

    Cost-effective BRCA Testing in Advanced Ovarian Cancer.

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2022 Dec 21 [2023 Jan 1];179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.
    • Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    • Shu T, Zhou Z, Bai J, Xiao X, Gao M, Zhang N, Wang H, Xia X, Gao Y, Zheng H.
    • Gynecol Oncol. 2023 Jan;168:135-143. doi: 10.1016/j.ygyno.2022.11.013. Epub 2022 Nov 25.
    • Lessons learned with a longer follow-up from SOLO 1.
    • Paulino E.
    • J Gynecol Oncol. 2023 Jan;34:e29. doi: 10.3802/jgo.2023.34.e29. Epub 2022 Dec 7.
    • STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    • Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z, Cheng X, Qian C, Xie S, Kim HJ, Launonen IM, Färkkilä A, Roberts TM, Freeman GJ, Liu JF, Konstantinopoulos PA, Matulonis U, Yu H, Zhao JJ.
    • J Immunother Cancer. 2023 Jan;11(1):e005627. doi: 10.1136/jitc-2022-005627.
    • Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
    • Kim ET, Jeong HE, Yoon HJ, Kim KH, Suh DS.
    • Taiwan J Obstet Gynecol. 2023 Jan;62(1):66-70. doi: 10.1016/j.tjog.2022.07.010.
    • Exploration of Chemotherapy-Free Regimen After Multi-Line Chemotherapy-Induced Renal Impairment in Recurrent Ovarian Cancer: Case Report and Literature Review.
    • Zhang LP, Yang X, Zheng W, Feng KX, Li H.
    • Front Oncol. 2022 Dec 29;12:1031045. doi: 10.3389/fonc.2022.1031045.
    • Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer.
    • Perez-Villatoro F, Oikkonen J, Casado J, Chernenko A, Gulhan DC, Tumiati M, Li Y, Lavikka K, Hietanen S, Hynninen J, Haltia UM, Tyrmi JS, Laivuori H, Konstantinopoulos PA, Hautaniemi S, Kauppi L, Färkkilä A.
    • NPJ Precis Oncol. 2022 Dec 29;6(1):96. doi: 10.1038/s41698-022-00339-8.
    • Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
    • Vertechy L, Boccia SM, Tiberi G, Avesani G, Corrado G, Fagotti A, Scambia G, Marchetti C.
    • Int J Gynecol Cancer. 2022 Dec 23:ijgc-2022-003764. doi: 10.1136/ijgc-2022-003764. Epub ahead of print.
    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.
    • CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    • Lu X, He Y, Johnston RL, Nanayakarra D, Sankarasubramanian S, Lopez JA, Friedlander M, Kalimutho M, Hooper JD, Raninga PV, Khanna KK.
    • J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.
    • Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
    • Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
    • J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.
    • Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity.
    • Wang W, Xiong Y, Hu X, Lu F, Qin T, Zhang L, Guo E, Yang B, Fu Y, Hu D, Fan J, Qin X, Liu C, Xiao R, Chen G, Li Z, Sun C.
    • Acta Biomater. 2022 Dec 19:S1742-7061(22)00824-8. doi: 10.1016/j.actbio.2022.12.021. Epub ahead of print.
    • Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.
    • Alatise KL, Gardner S, Alexander-Bryant A.
    • Cancers (Basel). 2022 Dec 18;14(24):6246. doi: 10.3390/cancers14246246.
    • Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer.
    • Seymour C.
    • OncLive. 2022 Dec 16.

    Related:

    •• Identifier: NCT03705156: Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient. (ClinicalTrials.gov . Accessed 2022 Dec 16.)

    • Towards Personalized Management of Ovarian Cancer.
    • Algethami M, Kulkarni S, Sadiq MT, Tang HKC, Brownlie J, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S.
    • Cancer Manag Res. 2022 Dec 15;14:3469-3483. doi: 10.2147/CMAR.S366681.
    • Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report.
    • Bian Y, Guan P, Li D, Tan L, Pang H, Wen Q, Chen P, Zhang Z.
    • Front Oncol. 2022 Dec 15;12:1071383. doi: 10.3389/fonc.2022.1071383.
    • Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    • Ding H, He C, Tong Y, Fang Q, Mi X, Chen L, Xin W, Fang L.
    • PLoS One. 2022 Dec 15;17(12):e0279286. doi: 10.1371/journal.pone.0279286.
    • First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer.
    • Roy S, Ghosh J, Ganguly S, Biswas B, Bhaumik J.
    • Cureus. 2022 Dec 13;14(12):e32493. doi: 10.7759/cureus.32493.
    • Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.
    • Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z.
    • Front Oncol. 2022 Dec 12;12:1010158. doi: 10.3389/fonc.2022.1010158.
    • SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib.
    • Markman M.
    • Medscape Oncology. Perspective. 2022 Dec 12.

    Related:

    •• Original research:

    Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.

    • Evaluation of external validity of the OVHIPEC-1 trial in a real-world population.
    • van Stein RM, Sikorska K, van der Aa MA, Sonke GS, van Driel WJ; Dutch OVHIPEC-1 trial group.
    • Int J Gynaecol Obstet. 2022 Dec 10. doi: 10.1002/ijgo.14618. Epub ahead of print.
    • BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
    • Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
    • Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
    • Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    • Kristeleit RS, Drew Y, Oza AM, Domchek SM, Banerjee S, Glasspool RM, Balmaña J, Chen LM, Patel MR, Burris HA, Safra T, Borrow J, Lin KK, Goble S, Maloney L, Shapira-Frommer R.
    • Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02022-y. Epub ahead of print.

    Related:

    •• Identifier: NCT01482715: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Dec 9.)

    • Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment.
    • Wang C, Gao P, Xu J, Liu S, Tian W, Liu J, Zhou L.
    • Front Pharmacol. 2022 Dec 7;13:1078303. doi: 10.3389/fphar.2022.1078303.
    • Patient-reported outcomes associated with reflex BRCA1/2 tumor and subsequent germline panel genetic testing for high-grade serous ovarian cancer.
    • McCuaig JM, Stockley TL, Ferguson SE, Vicus D, Brennenstuhl S, Ott K, Kim RH, Metcalfe KA.
    • J Genet Couns. 2022 Dec 7. doi: 10.1002/jgc4.1661. Epub ahead of print.
    • Olaparib Plus Durvalumab and Bevacizumab Provides Durable Survival in Non-Germline, BRCA+ Relapsed Ovarian Cancer.
    • Seymour C.
    • OncLive. 2022 Dec 4.

    Related:

    •• Identifier: NCT02734004: A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA). (ClinicalTrials.gov . Accessed 2022 Dec 4.)

    • Advances in small molecule maintenance therapies for high-grade serous ovarian cancer.
    • Fischetti M, Di Donato V, Palaia I, Perniola G, Tomao F, Perrone C, Giancotti A, Di Mascio D, Monti M, Muzii L, Benedetti Panici P, Bogani G.
    • Expert Opin Pharmacother. 2022 Dec 2. doi: 10.1080/14656566.2022.2154144. Epub ahead of print.
    • Review
    • The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
    • Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, Nowis D.
    • Front Mol Biosci. 2022 Dec 1;9:1073797. doi: 10.3389/fmolb.2022.1073797.
    • Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
    • Bhatt A, Bhandoria G, Kepenekian V, Bakrin N, Glehen O.
    • Int J Cancer. 2022 Dec 1;151(11):2055-2056. doi: 10.1002/ijc.34220. Epub 2022 Aug 5.
    • Comment. Letter.

    Related:

    Reply, Letter:

    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    Original research:

    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.

    • The use of Ctrough for the therapeutic drug monitoring of olaparib in patients with ovarian cancer.
    • Stanisławiak-Rudowicz J, Szałek E, Grzebalska M, Urjasz H, Michalak M, Mądry R, Grześkowiak E.
    • Eur Rev Med Pharmacol Sci. 2022 Dec;26(24):9426-9436. doi: 10.26355/eurrev_202212_30694.
    • Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    • O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, Swisher EM, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL.
    • Gynecol Oncol. 2022 Dec;167(3):404-413. doi: 10.1016/j.ygyno.2022.08.021. Epub 2022 Oct 20.

    Related:

    •• Identifier: NCT01968213: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3). (ClinicalTrials.gov . Accessed 2022 Oct 22.)

    •• Letter:

    AML and MDS associated with PARP inhibitor treatment of ovarian cancer.

    •• Reply, Letter:

    Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".

    •• Podcast: December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad. (Gynecologic Oncology. Podcasts.)

    • December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad.
    • Matulonis U, O'Malley D.
    • Gynecol Oncol. Podcasts. 2022 Dec.

    Related:

    •• Original research:

    Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.

    • Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer - Navigating maintenance therapy for homologous recombinant proficient ovarian cancer.
    • Goldsberry WN, Norquist BS, Rocconi RP, Modesitt SC, Urban RR.
    • Gynecol Oncol Rep. 2022 Nov 8 [eCollection 2022 Dec];44:101103. doi: 10.1016/j.gore.2022.101103.
    • Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations.
    • Sanders BE, Wolsky R, Doughty ES, Wells KL, Ghosh D, Ku L, Pressey JG, Bitler BB, Brubaker LW.
    • Gynecol Oncol Rep. 2022 Oct 6 [eCollection 2022 Dec];44:101077. doi: 10.1016/j.gore.2022.101077.
    • ATR Inhibitors in Platinum-Resistant Ovarian Cancer.
    • Li S, Wang T, Fei X, Zhang M.
    • Cancers (Basel). 2022 Nov 29;14(23):5902. doi: 10.3390/cancers14235902.
    • Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    • Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL.
    • Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.11.003. Epub ahead of print.
    • [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study.
    • Pantel AR, Gitto SB, Makvandi M, Kim H, Medvedv S, Weeks JK, Torigian DA, Hsieh CJ, Ferman B, Latif NA, Tanyi JL, Martin LP, Lanzo SM, Liu F, Cao Q, Mills GB, Doot RK, Mankoff DA, Mach RH, Lin LL, Simpkins F.
    • Clin Cancer Res. 2022 Nov 28:CCR-22-1602. doi: 10.1158/1078-0432.CCR-22-1602. Epub ahead of print.

    Related:

    •• Commentary:

    Shedding light on PARP inhibitor response through functional imaging.

    • Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
    • Viet Le B, Podszywalow-Bartnicka P, Piwocka K, Skorski T.
    • Cancers (Basel). 2022 Nov 24;14(23):5795. doi: 10.3390/cancers14235795.
    • Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
    • Murciano-Goroff YR, Schram AM, Rosen EY, Won H, Gong Y, Noronha AM, Janjigian YY, Stadler ZK, Chang JC, Yang SR, Mandelker D, Offit K, Berger MF, Donoghue MTA, Bandlamudi C, Drilon A.
    • Nat Commun. 2022 Nov 23;13(1):7182. doi: 10.1038/s41467-022-34109-8.
    • Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    • Li J, Li Q, Zhang L, Zhang S, Dai Y.
    • Biomed Pharmacother. 2022 Nov 18;157:114028. doi: 10.1016/j.biopha.2022.114028. Epub ahead of print.
    • FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer.
    • Harris J.
    • OncLive. 2022 Nov 18.
    • Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    • Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.

    Related:

    •• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy.
    • Soni A, Lin X, Mladenov E, Mladenova V, Stuschke M, Iliakis G.
    • Cancers (Basel). 2022 Nov 16;14(22):5619. doi: 10.3390/cancers14225619.
    • Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
    • Franzese O, Graziani G.
    • Cancers (Basel). 2022 Nov 16;14(22):5633. doi: 10.3390/cancers14225633.
    • Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
    • Todisco E, Gigli F, Ronchini C, Amato V, Sammassimo S, Pastano R, Parma G, Lapresa MT, Bertolini F, Corsini C, Gregato G, Poletti C, Pelicci PG, Alcalay M, Colombo N, Tarella C.
    • Int J Cancer. 2022 Nov 15;151(10):1791-1803. doi: 10.1002/ijc.34162. Epub 2022 Jul 2.
    • Dose Adjustment of Poly (ADP-Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
    • Zhao D, Long X, Wang J.
    • Drug Des Devel Ther. 2022 Nov 14;16:3947-3955. doi: 10.2147/DDDT.S387920.
    • Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.
    • Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ.
    • Cancers (Basel). 2022 Nov 12;14(22):5559. doi: 10.3390/cancers14225559.
    • PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer.
    • Doherty K, Miller EM.
    • OncLive. 2022 Nov 10.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 12: Investigative Therapies in Recurrent Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Nov 10.
    • Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
    • Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, Alarcón J, Calzas J, Gaba L, Fuentes J, Santaballa A, Salvador C, Manso L, Herrero A, Taus Á, Márquez R, Madani J, Merino M, Marquina G, Casado V, Constenla M, Gutiérrez M, Dosil A, González-Martín A.
    • BMC Cancer. 2022 Nov 8;22(1):1150. doi: 10.1186/s12885-022-10191-5.
    • Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse.
    • Washington CR, Moore KN.
    • Curr Oncol Rep. 2022 Nov 8. doi: 10.1007/s11912-022-01337-6. Epub ahead of print.
    • Review
    • Study: More is not better: PARP dose can be safely reduced for people with ovarian cancer.
    • [No author given]
    • FORCE. XRAY. 2022 Nov 8.

    Related:

    •• Original research:

    The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

    • Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
    • De Jong D, Otify M, Chen I, Jackson D, Jayasinghe K, Nugent D, Thangavelu A, Theophilou G, Laios A.
    • Medicina (Kaunas). 2022 Nov 8;58(11):1611. doi: 10.3390/medicina58111611.
    • Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
    • Giuliani J, Mantoan B, Ferrario L, Candela MV, Aprile G.
    • J Oncol Pharm Pract. 2022 Nov 7:10781552221137705. doi: 10.1177/10781552221137705. Epub ahead of print.
    • ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    • Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
    • Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12681-z. Epub ahead of print.
    • Review

    Related:

    •• Original research:

    Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

    • Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study.
    • Garcia-Casado Z, Oaknin A, Mendiola M, Alkorta-Aranburu G, Antunez-Lopez JR, Moreno-Bueno G, Palacios J, Yubero A, Marquez R, Gallego A, Sanchez-Heras AB, Lopez-Guerrero JA, Perez-Segura C, Barretina-Ginesta P, Alarcon J, Gaba L, Marquez A, Matito J, Cueva J, Palacio I, Iglesias M, Arcusa A, Sanchez-Lorenzo L, Guerra-Alia E, Romero I, Vivancos A.
    • J Pers Med. 2022 Nov 4;12(11):1842. doi: 10.3390/jpm12111842.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Nov 4.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 10: Antibody-Drug Conjugates in Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Nov 4.
    • BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance.
    • Scott R, Rimel BJ.
    • OncLive. 2022 Nov 3.
    • Sequential Olaparib, Adavosertib Administration Overcomes Concurrent Use Toxicity Problems.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 2.
    • The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    • Atwal A, Snowsill T, Dandy MC, Krum T, Newton C, Evans DG, Crosbie EJ, Ryan NAJ.
    • Int J Cancer. 2022 Nov 1;151(9):1626-1639. doi: 10.1002/ijc.34165. Epub 2022 Jul 6.
    • Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability.
    • Yuan W, Ni J, Wen H, Shi W, Chen X, Huang H, Zhang X, Lu X, Zhu C, Dong H, Yang S, Wu X, Chen X.
    • BJOG. 2022 Nov;129 Suppl 2:14-22. doi: 10.1111/1471-0528.17324.
    • The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study.
    • Zeng S, Chi J, Liu J, Jiao X, Liu X, Yu Y, Li R, Huo Y, Ma G, Zhao Y, Wang L, Zhou Q, Zou D, Cheng X, Li Q, Wang J, Yao S, Zhao W, Xia B, Chen Y, Fan J, Wang W, Hong L, Guo R, Liu Z, Gao Y, Li J, Zhang B, Yu J, Hu T, Zhang W, Shan W, Peng Z, Li M, Xie X, Ma D, Gao Q.
    • BJOG. 2022 Nov;129 Suppl 2:60-69. doi: 10.1111/1471-0528.17328.
    • [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
    • Tanaka Y, Oota R, Takagi Y, Kodama W, Nishimura K, Hamasaki T, Fukino S, Suo K.
    • Gan To Kagaku Ryoho. 2022 Nov;49(11):1271-1273. Japanese.
    • Case report. [Article in Japanese]
    • Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.
    • Caeiro C, Leão I, Oliveira I, Sousa I, André T.
    • Adv Ther. 2022 Nov;39(11):5289-5299. doi: 10.1007/s12325-022-02259-2. Epub 2022 Sep 5.
    • Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    • Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S.
    • Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.

    Related:

    Identifier: NCT02408536: Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22). (ClinicalTrials.gov)

    • Germline and somatic variants in ovarian carcinoma: a next-generation sequencing (NGS) analysis.
    • Andrikopoulou A, Zografos E, Apostolidou K, Kyriazoglou T, Papatheodoridi AM, Kaparelou M, Koutsoukos K, Liontos M, Dimopoulos M, Zagouri F.
    • Front Oncol. 2022 Oct 31;12:1030786. doi: 10.3389/fonc.2022.1030786.
    • Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
    • Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
    • Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 27.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 8: PARP Inhibitor Resistance in Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 27.
    • Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    • Chu YY, Yam C, Yamaguchi H, Hung MC.
    • J Biomed Sci. 2022 Oct 25;29(1):86. doi: 10.1186/s12929-022-00870-7.
    • Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer.
    • DiSilvestro PA.
    • OncLive. 2022 Oct 24.

    Related:

    •• Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov . Accessed 2022 Oct 25)

    • Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer.
    • Zamwar UM, Anjankar AP.
    • Cureus. 2022 Oct 21;14(10):e30561. doi: 10.7759/cureus.30561.
    • Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    • Zhang Y, Zhang L, Zhao Y, Wang S, Feng L.
    • Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867.

    Related:

    •• Review registration number: CRD42022300367: Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. (PROSPERO register. Accessed 2022 Nov 7.)

    • Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
    • Kwon JS, Tinker AV, Santos J, Compton K, Sun S, Schrader KA, Karsan A.
    • JCO Precis Oncol. 2022 Oct [20];6:e2200033. doi: 10.1200/PO.22.00033.
    • SOLO-1 Data Support Use of Olaparib Maintenance to Achieve Long-Term Remission in BRCA+ Advanced Ovarian Cancer.
    • Flaherty C, DiSilvestro PA.
    • OncLive. 2022 Oct 20.

    Related:

    Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov . Accessed 2022 Oct 20.)

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 20.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 20.
    • Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    • Cheng A, Rao Q, Liu Y, Huang C, Li J, Huo C, Lin Z, Lu H.
    • Gynecol Oncol. 2022 Oct 18:S0090-8258(22)01888-1. doi: 10.1016/j.ygyno.2022.10.011. Epub ahead of print.
    • Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer.
    • Karlan BY.
    • OncLive. OncLive TV. 2022 Oct 18.
    • Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report.
    • Biswas G.
    • Cureus. 2022 Oct 17;14(10):e30405. doi: 10.7759/cureus.30405.
    • The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    • Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z.
    • J Hematol Oncol. 2022 Oct 17;15(1):147. doi: 10.1186/s13045-022-01360-x.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.
    • Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
    • Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC.
    • Int J Cancer. 2022 Oct 15;151(8):1394-1404. doi: 10.1002/ijc.34124. Epub 2022 Jun 4.

    Related:

    Comment, Letter:

    Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    Reply, Letter:

    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    • Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status.
    • Scott R, González-Martín A.
    • OncLive. 2022 Oct 12.

    Related:

    Conference abstract:

    530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety.

    Identifier: NCT02655016: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Oct 12.)

    Video: Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer. (OncLive TV)

    • Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
    • Huang TT, Burkett SS, Tandon M, Yamamoto TM, Gupta N, Bitler BG, Lee JM, Nair JR.
    • Oncogene. 2022 Oct 12. doi: 10.1038/s41388-022-02491-8. Epub ahead of print.
    • SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
    • Lin S, Tian J, He Q, Yang M, Chen Z, Belogurov AA Jr, Li X, Zhang F, Liu Y, Chen G.
    • Dis Markers. 2022 Oct 11;2022:7243146. doi: 10.1155/2022/7243146.
    • Therapy related myeloid neoplasms following PARP inhibitors: real-life experience.
    • Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB.
    • Clin Cancer Res. 2022 Oct 6:CCR-22-1622. doi: 10.1158/1078-0432.CCR-22-1622. Epub ahead of print.
    • Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
    • Marchetti C, Fagotti A, Scambia G.
    • J Clin Oncol. 2022 Oct 6:JCO2201585. doi: 10.1200/JCO.22.01585. Epub ahead of print.

    Related:

    Letter, Reply:

    Reply to C. Marchetti et al.

    Original research:

    A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).

    • Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer.
    • Huepenbecker SP, Wright JD, Downer MK, Incerti D, Luhn P, Dolado I, Bastiere-Truchot L, Lin YG, Chan JK, Meyer LA.
    • Obstet Gynecol. 2022 Oct 6. doi: 10.1097/AOG.0000000000004958. Epub ahead of print.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 1: Recent Updates in PARP Inhibitor Indications for Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 6.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 2: PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 6.
    • Update: PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer.
    • [No author given]
    • FORCE. XRAY. 2022 Oct 4.

    Related:

    Conference abstract: 518O - Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation. (OncologyPRO)

    Identifier: NCT02855944: ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients. (ClinicalTrials.gov)

    • Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study.
    • Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Kawasaki T, Furukawa T, Nakamura T.
    • Front Oncol. 2022 Oct 4;12:898150. doi: 10.3389/fonc.2022.898150.
    • Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
    • Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA.
    • Onco Targets Ther. 2022 Oct 4;15:1105-1117. doi: 10.2147/OTT.S272199.
    • Differential histone deacetylase inhibitor-induced perturbations of the global proteome landscape in the setting of high-grade serous ovarian cancer.
    • Duda JM, Twigg CAI, Thomas SN.
    • Proteomics. 2022 Oct 4:e2100372. doi: 10.1002/pmic.202100372. Epub ahead of print.
    • Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
    • Lee JM, Moore RG, Ghamande S, Park MS, Diaz JP, Chapman J, Kendrick J, Slomovitz BM, Tewari KS, Lowe ES, Milenkova T, Kumar S, Dymond M, Brown J, Liu JF.
    • Clin Cancer Res. 2022 Oct 3;28(19):4186-4193. doi: 10.1158/1078-0432.CCR-21-1733.

    Related:

    Identifier: NCT02889900: Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO). (ClinicalTrials.gov)

    • Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
    • Zhang X, Huo X, Guo H, Xue L.
    • Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.
    • A First-in-Class Clinical G-Quadruplex-Targeting Drug. The Bench-to-Bedside Translation of the Fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
    • Xu H, Hurley LH.
    • Bioorg Med Chem Lett. 2022 Oct 1:129016. doi: 10.1016/j.bmcl.2022.129016. Epub ahead of print.
    • Review

    Related:

    Original research:

    Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov)

    • Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    • Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E.
    • Ann Oncol. 2022 Oct;33(10):1021-1028. doi: 10.1016/j.annonc.2022.06.011. Epub 2022 Jun 27.

    Related:

    Commentary:

    Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?

    • Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    • Gadducci A, Cosio S, Lippolis PV.
    • Anticancer Res. 2022 Oct;42(10):4659-4665. doi: 10.21873/anticanres.15970.
    • Prognostic Significance of Clinical Factors Including BRCA Mutation in Epithelial Ovarian, Peritoneal, Fallopian Tube Cancer.
    • Kim JY, Park H, Lee DW, Kim MJ, Shin JE, Lee KE, Lee HN.
    • Anticancer Res. 2022 Oct;42(10):4945-4954. doi: 10.21873/anticanres.16001.
    • Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    • Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J.
    • Br J Cancer. 2022 Oct;127(6):1123-1132. doi: 10.1038/s41416-022-01900-9. Epub 2022 Jun 25.
    • An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation.
    • Mahima M, Mahmood T, Ved A, Siddiqui MH, Ahsan F, Shamim A, Ansari VA, Ahmad A, Kashyap MK.
    • Drug Res (Stuttg). 2022 Oct;72(8):424-434. doi: 10.1055/a-1867-4654. Epub 2022 Jun 27. Erratum in: Drug Res (Stuttg). 2022 Jul 26;:
    • Review
    • Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    • Gulia S, Kannan S, Ghosh J, Rath S, Maheshwari A, Gupta S.
    • ESMO Open. 2022 Oct;7(5):100558. doi: 10.1016/j.esmoop.2022.100558. Epub 2022 Aug 22.
    • Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
    • Yoshihama T, Kuroda Y, Chiyoda T, Takahashi M, Yoshimura T, Saotome K, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Aoki D.
    • Int J Clin Oncol. 2022 Oct;27(10):1644-1650. doi: 10.1007/s10147-022-02212-x. Epub 2022 Jul 15.
    • A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
    • Konstantinopoulos PA, Lee JM, Gao B, Miller R, Lee JY, Colombo N, Vergote I, Credille KM, Young SR, McNeely S, Wang XA, Lin AB, Shapira-Frommer R.
    • Gynecol Oncol. 2022 Sep 30:S0090-8258(22)01839-X. doi: 10.1016/j.ygyno.2022.09.019. Epub ahead of print.
    • Homologous recombination deficiency (HRD) as an ovarian cancer biomarker in a real-world cohort - validation of decentralized genomic profiling.
    • Denkert C, Romey M, Swedlund B, Hattesohl A, Teply-Szymanski J, Kommoss S, Kaiser K, Staebler A, du Bois A, Grass A, Knappmeyer C, Heitz F, Solimeno C, Ebel T, Harter P, Marmé F, Jank P, Gaiser T, Neff C, Wagner U, Timms KM, Rodepeter F.
    • J Mol Diagn. 2022 Sep 30:S1525-1578(22)00266-5. doi: 10.1016/j.jmoldx.2022.09.004. Epub ahead of print.
    • Deciphering the expression patterns of homologous recombination-related lncRNAs identifies new molecular subtypes and emerging therapeutic opportunities in epithelial ovarian cancer.
    • Hua T, Zhang XC, Wang W, Tian YJ, Chen SB.
    • Front Genet. 2022 Sep 29;13:901424. doi: 10.3389/fgene.2022.901424.
    • Integrated proteomics identifies PARP inhibitor-induced pro-survival signaling changes as potential vulnerabilities in ovarian cancer.
    • Deng O, Dash S, Nepomuceno TC, Fang B, Yun SY, Welsh EA, Lawrence HR, Marchion D, Koomen JM, Monteiro AN, Rix U.
    • J Biol Chem. 2022 Sep 29:102550. doi: 10.1016/j.jbc.2022.102550. Epub ahead of print.
    • Inherited heterozygous Fanconi anemia gene mutations in a therapy-related CMML patient with a rare NUP98-HOXC11 fusion: a case report and literature review.
    • Shen K, Zhang M, Wang J, Mu W, Wang J, Wang C, Xing S, Hong Z, Xiao M.
    • Front Oncol. 2022 Sep 28;12:1036511. doi: 10.3389/fonc.2022.1036511.
    • RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer.
    • Han GH, Shim JE, Yun H, Kim J, Kim JH, Cho H.
    • J Gene Med. 2022 Sep 28:e3452. doi: 10.1002/jgm.3452. Epub ahead of print.
    • [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    • Wang DF, Zhang J, Zhang C, Yu J, Shi Y, Xu SQ, Fan Y, Zhou FZ, Song SQ, Liu H, Zhang GN.
    • Zhonghua Fu Chan Ke Za Zhi. 2022 Sep 25;57(9):641-652. Chinese. doi: 10.3760/cma.j.cn112141-20220728-00490.
    • [Article in Chinese]
    • Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial.
    • Chen J, Li Y, Wang H, Li T, Gu Y, Wang W, Shan Y, Yin J, Wang Y, Qin M, Li S, Pan L, Peng S, Jin Y.
    • Cancers (Basel). 2022 Sep 24;14(19):4649. doi: 10.3390/cancers14194649.
    • Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
    • Xie T, Dickson KA, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ.
    • Cancers (Basel). 2022 Sep 23;14(19):4621. doi: 10.3390/cancers14194621.
    • Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    • Tew WP, Lacchetti C, Kohn EC; PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel.
    • J Clin Oncol. 2022 Sep 23:JCO2201934. doi: 10.1200/JCO.22.01934. Epub ahead of print.
    • Increased Risk for Death Prompts Withdrawal of Three PARPi Indications for Ovarian Cancer.
    • Worcester S.
    • Medscape. 2022 Sep 23.
    • Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study.
    • Heemskerk-Gerritsen BAM, Hollestelle A, van Asperen CJ, van den Beek I, van Driel WJ, van Engelen K, Gómez Garcia EB, de Hullu JA, Koudijs MJ, Mourits MJE, Hooning MJ, Boere IA.
    • PLoS One. 2022 Sep 22;17(9):e0275015. doi: 10.1371/journal.pone.0275015.
    • Niraparib-induced STAT3 inhibition increases its antitumor effects.
    • Yu HE, Rodriguez-Rodriguez L, Zhao Q, Kohut A, Li YJ, Martincuks A, Austria T, Zhang C, Santiago NL, Borrero RM, Phan XT, Melstrom L.
    • Front Oncol. 2022 Sep 21;12:966492. doi: 10.3389/fonc.2022.966492.
    • Novel approach of desensitization in allergic reaction to Olaparib.
    • Beurer BM, Sprenger LM, Graneß K, Feldmann F, Warnke U, Biersack MG, Fischer D.
    • J Oncol Pharm Pract. 2022 Sep 21:10781552221124041. doi: 10.1177/10781552221124041. Epub ahead of print.
    • Case report
    • Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel.
    • Salvati A, Carnevali I, Alexandrova E, Facchi S, Ronchi S, Libera L, Sahnane N, Memoli D, Lamberti J, Amabile S, Pepe S, Tarallo R, Sessa F, Weisz A, Tibiletti MG, Rizzo F.
    • Exp Mol Pathol. 2022 Sep 20;128:104833. doi: 10.1016/j.yexmp.2022.104833. Epub ahead of print.
    • Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    • Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, Sanhaji M.
    • Int J Mol Sci. 2022 Sep 17;23(18):10892. doi: 10.3390/ijms231810892.
    • Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer.
    • Guy H, Hawkes C, Walder L, Malinowska IA, Gupta D.
    • Future Oncol. 2022 Sep 14:0. doi: 10.2217/fon-2022-0578. Epub ahead of print.
    • Reassuring Data: Olaparib Dose Reductions Have Minimal Effect.
    • Markman M.
    • Medscape Oncology. 2022 Sep 14.

    Related:

    Original research:

    The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

    • Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
    • Romeo M, Gil-Martín M, Gaba L, Teruel I, Taus Á, Fina C, Masvidal M, Murata P, Fernández-Plana J, Martínez A, Pérez C, García Y, Rodriguez V, Cros S, Parera M, Zanui M, Catot S, Pardo B, Plaja A, Esteve A, Barretina-Ginesta MP.
    • Cancers (Basel). 2022 Sep 11;14(18):4414. doi: 10.3390/cancers14184414.
    • Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2022 Sep 10.
    • Conference report
    • Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    • Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
    • Ann Surg Oncol. 2022 Sep 9. doi: 10.1245/s10434-022-12459-3. Epub ahead of print.

    Related:

    •• Review:

    ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

    • Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
    • Bound NT, Vandenberg CJ, Kartikasari AER, Plebanski M, Scott CL.
    • Front Genet. 2022 Sep 9;13:886170. doi: 10.3389/fgene.2022.886170.
    • Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
    • DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators.
    • J Clin Oncol. 2022 Sep 9:JCO2201549. doi: 10.1200/JCO.22.01549. Epub ahead of print.

    Related:

    •• Identifier: NCT01844986: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). (ClinicalTrials.gov)

    •• Video, Research news: SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib. (Medscape Oncology)

    • Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients.
    • Grech CT, Pils D, Aust S, Grimm C, Polterauer S, Reinthaller A, Müllauer L, Reischer T, Bekos C.
    • J Pers Med. 2022 Sep 7;12(9):1467. doi: 10.3390/jpm12091467.
    • Next-generation sequencing based detection of BRCA1 and BRCA2 large genomic rearrangements in Chinese cancer patients.
    • Hua D, Tian Q, Wang X, Bei T, Cui L, Zhang B, Bao C, Bai Y, Zhao X, Yuan P.
    • Front Oncol. 2022 Sep 6;12:898916. doi: 10.3389/fonc.2022.898916.
    • Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    • González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, Vergote I, Colombo N, Mirza MR, Tazi Y, Canzler U, Zamagni C, Guerra-Alia EM, Levaché CB, Marmé F, Bazan F, de Gregorio N, Dohollou N, Fasching PA, Scambia G, Rubio-Pérez MJ, Milenkova T, Costan C, Pautier P, Ray-Coquard I; PAOLA1/ENGOT-ov25 investigators.
    • Eur J Cancer. 2022 Sep 3;174:221-231. doi: 10.1016/j.ejca.2022.07.022. Epub ahead of print.
    • Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer.
    • Bhatt A, Sinukumar S, Kepenekian V, Kammar P, Mehta S, Shaikh S, Gertych W, Bakrin N, Glehen O.
    • Front Oncol. 2022 Sep 2;12:951419. doi: 10.3389/fonc.2022.951419.
    • Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    • Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, Lønning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM.
    • Clin Cancer Res. 2022 Sep 1:CCR-22-0749. doi: 10.1158/1078-0432.CCR-22-0749. Epub ahead of print.

    Related:

    Identifier: NCT01623349: Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer. (ClinicalTrials.gov)

    Identifier: NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC). (ClinicalTrials.gov)

    • 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety.
    • Gonzalez Martin AJ, Pothuri B, Vergote IB, Graybill W, Mirza MR, Mccormick C, Lorusso D, Freyer G, Backes F, Baumann KH, Redondo Sanchez A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska I, Shtessel L, Compton N, Monk BJ.
    • Ann Oncol. 2022 Sep 1;33(7 Suppl):S789. doi: 10.1016/j.annonc.2022.07.658.
    • Conference abstract

    Related:

    Identifier: NCT02655016: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Oct 12.)

    Conference news: Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status. (OncLive)

    • Metastatic involvement of inguinal lymph nodes as the first sign of endometroid carcinoma of the fallopian tube.
    • Maradová E, Jánošík M, Pilka R, Marek R.
    • Ceska Gynekol. 2022 Fall;87(5):328-332. English. doi: 10.48095/cccg2022328.
    • Case report
    • Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    • Chen T, Yu T, Zhuang S, Geng Y, Xue J, Wang J, Ai L, Chen B, Zhao Z, Li Y, Wang J, Liang H, Xu Y, Gu Y.
    • Br J Cancer. 2022 Sep;127(5):916-926. doi: 10.1038/s41416-022-01836-0. Epub 2022 May 26.
    • Maintenance therapy with PARP inhibition in ovarian cancer.
    • Herzog TJ.
    • Clin Adv Hematol Oncol. 2022 Sep;20(9):539-541.
    • Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    • Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C.
    • Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5.

    Related:

    Identifier: NCT02983799: Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status. (ClinicalTrials.gov)

    • RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
    • Liu P, Lin C, Liu L, Lu Z, Tu Z, Liu H.
    • J Biol Chem. 2022 Sep;298(9):102354. doi: 10.1016/j.jbc.2022.102354. Epub 2022 Aug 9.
    • Long-term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report.
    • Bredow K, Blümcke B, Schneider S, Püsken M, Schmutzler R, Rhiem K.
    • Mol Clin Oncol. 2022 Jul 21 [eCollection 2022 Sep];17(3):137. doi: 10.3892/mco.2022.2570.
    • Comment on: BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Jia D, Li L, Wang P.
    • Target Oncol. 2022 Sep;17(5):605-606. doi: 10.1007/s11523-022-00903-z. Epub 2022 Aug 1.
    • Comment. Letter.

    Related:

    Original research:

    BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.

    Reply, Letter:

    Author's Reply to Jia et al.: "BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis".

    • Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.
    • Linz VC, Löwe A, van der Ven J, Hasenburg A, Battista MJ.
    • Front Oncol. 2022 Aug 31;12:951292. doi: 10.3389/fonc.2022.951292.
    • Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.
    • Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T.
    • Life (Basel). 2022 Aug 31;12(9):1355. doi: 10.3390/life12091355.
    • PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies.
    • Wang N, Yang Y, Jin D, Zhang Z, Shen K, Yang J, Chen H, Zhao X, Yang L, Lu H.
    • Front Pharmacol. 2022 Aug 25;13:967633. doi: 10.3389/fphar.2022.967633.
    • Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
    • Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F.
    • Cancers (Basel). 2022 Aug 21;14(16):4040. doi: 10.3390/cancers14164040.
    • What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China.
    • Zhang D, Li S, Zhang X, Peng J, Zhang S.
    • Front Oncol. 2022 Aug 18;12:955124. doi: 10.3389/fonc.2022.955124.
    • Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer.
    • Oda K, Aoki D, Tsuda H, Nishihara H, Aoyama H, Inomata H, Shimada M, Enomoto T.
    • Cancer Sci. 2022 Aug 17. doi: 10.1111/cas.15518. Epub ahead of print.
    • Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    • Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH.
    • Cancer. 2022 Aug 15;128(16):3080-3089. doi: 10.1002/cncr.34350. Epub 2022 Jun 17.
    • Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
    • Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Hallas-Potts A, Croy I, McCluggage WG, Williams ARW, Bartos C, Iida Y, Okamoto A, Dougherty B, Barrett JC, March R, Matakidou A, Roxburgh P, Semple CA, Harkin DP, Kennedy R, Herrington CS, Gourley C.
    • Clin Cancer Res. 2022 Aug 15;28(16):3546-3556. doi: 10.1158/1078-0432.CCR-22-0368.
    • Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
    • Shu Y, Liu Y, He X, Ding Y, Zhang Q.
    • Front Pharmacol. 2022 Aug 12;13:818579. doi: 10.3389/fphar.2022.818579.
    • BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside.
    • Boussios S, Rassy E, Moschetta M, Ghose A, Adeleke S, Sanchez E, Sheriff M, Chargari C, Pavlidis N.
    • Cancers (Basel). 2022 Aug 11;14(16):3888. doi: 10.3390/cancers14163888.
    • Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
    • Zhao Q, Ni J, Dong J, Cheng X, Xiao L, Xue Q, Xu X, Guo W, Chen X.
    • Reprod Sci. 2022 Aug 9. doi: 10.1007/s43032-022-01037-3. Epub ahead of print.
    • Case report
    • Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.
    • Goebel EA, Kerkhof J, Dzyubak O, McLachlin CM, McGee J, Sadikovic B.
    • Genes (Basel). 2022 Aug 6;13(8):1398. doi: 10.3390/genes13081398.
    • Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    • Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L.
    • J Clin Oncol. 2022 Aug 1;40(22):2436-2446. doi: 10.1200/JCO.21.01511. Epub 2022 Apr 11.

    Related:

    Identifier: NCT03863860: A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients. (ClinicalTrials.gov)

    • Liquid Biopsy Revealed HBOC Pedigree and Led to Medical Management Among the Relatives.
    • Ogawa C, Hirasawa A, Sogawa R, Hasuoka K, Tomida S, Futagawa M, Urakawa Y, Kochi M, Yamamoto H, Nakamura K, Masuyama H.
    • Acta Med Okayama. 2022 Aug;76(4):479-483. doi: 10.18926/AMO/63908.
    • A commentary on the discrepancy between blood and tumour BRCA testing: An open question.
    • De Paolis E, Marchetti C, Concolino P, Scambia G, Urbani A, Fagotti A, Minucci A.
    • BJOG. 2022 Aug;129(9):1422-1426. doi: 10.1111/1471-0528.17158. Epub 2022 Apr 5.

    Related:

    Commentary:

    Gene sequencing in ovarian cancer: continually moving targets.

    • BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
    • Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT.
    • Br J Cancer. 2022 Aug;127(3):488-499. doi: 10.1038/s41416-022-01823-5. Epub 2022 Apr 30.
    • Mutation profiles in circulating cell-free DNA predict acquired resistance to Olaparib in high-grade serous ovarian carcinoma.
    • Hu D, Guo E, Yang B, Qin X, Fu Y, Fan J, Zhuang X, Yao Q, Lu F, Li W, Xiao R, Wu X, Yang X, Wang Z, Liu C, You L, Zang R, Zhou Q, Zhao W, Chen G, Sun C.
    • Cancer Sci. 2022 Aug;113(8):2849-2861. doi: 10.1111/cas.15456. Epub 2022 Jun 26.
    • Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer.
    • Goh JCH, Gourley C, Tan DSP, Nogueira-Rodrigues A, Elghazaly H, Edy Pierre M, Giornelli G, Kim BG, Morales-Vasquez F, Tyulyandina A.
    • Gynecol Oncol Rep. 2022 Jun 17 [eCollection 2022 Aug];42:101028. doi: 10.1016/j.gore.2022.101028.
    • In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
    • Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, Vacirca D, Colombo N, Barberis M.
    • Pathologica. 2022 Aug;114(4):288-294. doi: 10.32074/1591-951X-791.
    • Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer.
    • Paracchini L, Mannarino L, Beltrame L, Landoni F, Fruscio R, Grassi T, Dalessandro ML, D'Incalci M, Marchini S.
    • Cancers (Basel). 2022 Jul 29;14(15):3697. doi: 10.3390/cancers14153697.
    • Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
    • Sabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, Provansal M, Cappiello M, Rousseau F, Chaffanet M, Birnbaum D, Mamessier E, Gonçalves A, Bertucci F.
    • Front Oncol. 2022 Jul 29;12:946257. doi: 10.3389/fonc.2022.946257.

    Related:

    Identifier: NCT02342158: Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors (PERMED01). (ClinicalTrials.gov)

    • PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.
    • Kim D, Nam HJ.
    • Int J Mol Sci. 2022 Jul 29;23(15):8412. doi: 10.3390/ijms23158412.
    • Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
    • Nag S, Aggarwal S, Rauthan A, Warrier N.
    • J Ovarian Res. 2022 Jul 28;15(1):88. doi: 10.1186/s13048-022-01020-1.
    • Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis.
    • Nguyen-Sträuli BD, Baum J, Meyer-Wilmes P, Kreklau A, Buschmann C, El Ouardi N, Fotopoulou C, Hummel M, Chekerov R, Braicu E, Sehouli J, Pietzner K.
    • Int J Gynecol Cancer. 2022 Jul 27:ijgc-2022-003637. doi: 10.1136/ijgc-2022-003637. Epub ahead of print.
    • DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers.
    • Gull N, Jones MR, Peng PC, Coetzee SG, Silva TC, Plummer JT, Reyes ALP, Davis BD, Chen SS, Lawrenson K, Lester J, Walsh C, Rimel BJ, Li AJ, Cass I, Berg Y, Govindavari JB, Rutgers JKL, Berman BP, Karlan BY, Gayther SA.
    • J Exp Clin Cancer Res. 2022 Jul 27;41(1):232. doi: 10.1186/s13046-022-02440-z.
    • Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges.
    • Nikolaidi A, Fountzilas E, Fostira F, Psyrri A, Gogas H, Papadimitriou C.
    • Front Oncol. 2022 Jul 26;12:820128. doi: 10.3389/fonc.2022.820128.
    • Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.
    • Monuszko KA, Fish LJ, Sparacio D, Lizaso C, Burn K, Wickenheisser NE, Meyer LA, Reed SD, Davidson BA, Havrilesky LJ.
    • Gynecol Oncol Rep. 2022 Jul 26;43:101050. doi: 10.1016/j.gore.2022.101050.
    • EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 25.
    • The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    • Lau CH, Seow KM, Chen KH.
    • Int J Mol Sci. 2022 Jul 23;23(15):8125. doi: 10.3390/ijms23158125.
    • Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance.
    • Palluzzi E, Marchetti C, Cappuccio S, Avesani G, Macchia G, Gambacorta MA, Cocciolillo F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 Jul 22:ijgc-2022-003543. doi: 10.1136/ijgc-2022-003543. Epub ahead of print.
    • CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    • You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM.
    • J Clin Oncol. 2022 Jul 22:JCO2200430. doi: 10.1200/JCO.22.00430. Epub ahead of print.
    • A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    • Shao C, Chang MS, Lam FC, Marley AR, Tang H, Song Y, Miller C, Brown M, Wan I, Han J, Adeboyeje G.
    • J Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475.
    • Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study.
    • Kim SI, Lim H, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Lee M.
    • Cancer Res Treat. 2022 Jul 19. doi: 10.4143/crt.2022.232. Epub ahead of print.
    • Comprehensive Genomic Profiling in the Management of Ovarian Cancer-National Results from Croatia.
    • Cerina D, Matkovic V, Katic K, Belac Lovasic I, Šeparovic R, Canjko I, Bajic Ž, Vrdoljak E.
    • J Pers Med. 2022 Jul 19;12(7):1176. doi: 10.3390/jpm12071176.
    • Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
    • Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M, Boussios S.
    • Int J Environ Res Public Health. 2022 Jul 14;19(14):8577. doi: 10.3390/ijerph19148577.
    • Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.
    • Chan VKY, Yang R, Wong ICK, Li X.
    • Front Pharmacol. 2022 Jul 11;13:891149. doi: 10.3389/fphar.2022.891149.
    • Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma.
    • Magalhães D, Bartosch C, Abreu MH.
    • Cureus. 2022 Jul 8;14(7):e26662. doi: 10.7759/cureus.26662.
    • AZD5305 More Tolerable than Earlier PARP Agents.
    • [No author given]
    • Cancer Discov. 2022 Jul 6;12(7):1602. doi: 10.1158/2159-8290.CD-NB2022-0039.
    • News
    • Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer.
    • Moore G, Majumdar R, Powell SN, Khan AJ, Weinhold N, Yin S, Higginson DS.
    • Mol Cancer Res. 2022 Jul 6;20(7):1061-1070. doi: 10.1158/1541-7786.MCR-21-1012.
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Related:

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
    • Sivakumaran T, Krasovitsky M, Freimund A, Lee YC, Webber K, So J, Norris C, Friedlander M, Mileshkin L, Au-Yeung G.
    • Int J Gynecol Cancer. 2022 Jul 4;32(7):906-912. doi: 10.1136/ijgc-2021-003009.
    • Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.
    • Zhang X, Wang L, Chen S, Huang P, Ma L, Ding H, Basappa B, Zhu T, Lobie PE, Pandey V.
    • Commun Med (Lond). 2022 Jul 2;2:82. doi: 10.1038/s43856-022-00142-3.
    • Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes.
    • Shah S, Cheung A, Kutka M, Sheriff M, Boussios S.
    • Int J Environ Res Public Health. 2022 Jul 1;19(13):8113. doi: 10.3390/ijerph19138113.
    • Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
    • Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA.
    • J Clin Oncol. 2022 Jul 1;40(19):2138-2147. doi: 10.1200/JCO.21.02011. Epub 2022 Mar 15.
    • Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.
    • Lee J, Kim JM, Lee YH, Chong GO, Lee NY, Lee IH, Park JY, Hong DG.
    • In Vivo. 2022 Jul-Aug;36(4):1903-1910. doi: 10.21873/invivo.12910.
    • Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
    • You B, Van Wagensveld L, Tod M, Sonke GS, Horlings HM, Kruitwagen RFPM, Du Bois A, Selle F, Perren T, Pfisterer J, Joly F, Cook A, Kaminsky MC, Wollschlaeger K, Lortholary A, Tome O, Leary A, Freyer G, Van Der Aa M, Colomban O.
    • Br J Cancer. 2022 Jul;127(1):79-83. doi: 10.1038/s41416-022-01732-7. Epub 2022 Mar 31.
    • Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.
    • González-Martín A, Matulonis UA, Korach J, Mirza MR, Moore KN, Wu X, York W, Gupta D, Lechpammer S, Monk BJ.
    • Future Oncol. 2022 Jul;18(23):2505-2536. doi: 10.2217/fon-2022-0206.
    • State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    • Hinchcliff E, Westin SN, Herzog TJ.
    • Gynecol Oncol. 2022 Jul;166(1):18-24. doi: 10.1016/j.ygyno.2022.04.021. Epub 2022 May 17.
    • Review
    • Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    • Fedier A, Maggi N, Tozzi A, Disler M, Coelho R, Jacob F, Heinzelmann-Schwarz V.
    • Int J Oncol. 2022 Jul;61(1):89. doi: 10.3892/ijo.2022.5379. Epub 2022 Jun 1.
    • Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    • Shi T, Xiang L, Zhu J, Liu J, Zhang P, Wang H, Feng Y, Zhu T, Zhang Y, Yu A, Jiang W, Wang X, Zhu Y, Wu S, Teng Y, Zhang J, Jiang R, Zhang W, Jia H, Zang R.
    • J Gynecol Oncol. 2022 Jul;33(4):e63. doi: 10.3802/jgo.2022.33.e63.

    Related:

    Original research:

    A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.

    • Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    • Lee JY, Kim BG, Kim JW, Lee JB, Park E, Joung JG, Kim S, Choi CH, Kim HS; Korean Gynecologic Oncology Group (KGOG) investigators.
    • J Gynecol Oncol. 2022 Jul;33(4):e45. doi: 10.3802/jgo.2022.33.e45. Epub 2022 Mar 4.

    Related:

    Identifier: NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION). (ClinicalTrials.gov)

    Commentary:

    A step towards the ambition of precision oncology in recurrent ovarian cancer.

    • Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations.
    • Ganguly S, Gogia A.
    • Lancet Oncol. 2022 Jul;23(7):e314. doi: 10.1016/S1470-2045(22)00325-4.

    Related:

    Letter, Reply:

    Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply.

    Original research:

    Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

    • BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study.
    • Li K, Zeng J, Zhang M, Yin R, Li Z.
    • Front Oncol. 2022 Jun 30;12:807748. doi: 10.3389/fonc.2022.807748.
    • A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report.
    • Ngu SF, Ngan HYS, Chan KKL.
    • Cancer Drug Resist. 2022 Jun 22;5(3):662-666. doi: 10.20517/cdr.2022.12.
    • A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
    • Tinker AV, Altman AD, Bernardini MQ, Ghatage P, Gien LT, Provencher D, Salvador S, Doucette S, Oza AM.
    • Curr Oncol. 2022 Jun 17;29(6):4354-4369. doi: 10.3390/curroncol29060348.
    • Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    • Mekonnen N, Yang H, Shin YK.
    • Front Oncol. 2022 Jun 17;12:880643. doi: 10.3389/fonc.2022.880643.
    • The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    • Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N.
    • Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
    • Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
    • Yi H, Li L, Huang J, Ma Z, Li H, Chen J, Zheng X, Chen J, He H, Song J.
    • Front Mol Biosci. 2022 Jun 13;9:906922. doi: 10.3389/fmolb.2022.906922.
    • Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jun 9.

    Related:

    Identifier: NCT02903004: Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO23). (ClinicalTrials.gov)

    • Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
    • Saito A, Tanioka M, Hirata M, Watanabe T, Odaka Y, Shimoi T, Sudo K, Noguchi E, Ishikawa M, Yonemori K.
    • Cancer Treat Res Commun. 2022 [Epub 2022 Jun 8];32:100587. doi: 10.1016/j.ctarc.2022.100587. Epub 2022 Jun 8.
    • Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis.
    • Luo J, Ou S, Wei H, Qin X, Jiang Q.
    • Front Oncol. 2022 Jun 8;12:815265. doi: 10.3389/fonc.2022.815265.
    • Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12.
    • Gallardo-Rincón D, Montes-Servín E, Alamilla-García G, Montes-Servín E, Bahena-González A, Cetina-Pérez L, Morales Vásquez F, Cano-Blanco C, Coronel-Martínez J, González-Ibarra E, Espinosa-Romero R, María Alvarez-Gómez R, Pedroza-Torres A, Castro-Eguiluz D.
    • Front Genet. 2022 Jun 6;13:863956. doi: 10.3389/fgene.2022.863956.
    • Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    • Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, Baldassarre G, Califano D, Capoluongo E, Costi MP, D'Incalci M, Marchini S, Mezzanzanica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S.
    • Int J Gynecol Cancer. 2022 Jun 6;32(6):799-803. doi: 10.1136/ijgc-2022-003435.
    • Study protocol

    Related:

    Clinical Trials: MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B) (ClinicalTrials.gov)

    • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
    • Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS.
    • J Clin Oncol. 2022 Jun 6:JCO2201003. doi: 10.1200/JCO.22.01003. Epub ahead of print.

    Related:

    Identifier: NCT03522246: A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA). (ClinicalTrials.gov)

    Letter, Commentary:

    Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.

    • Insights into the Possible Molecular Mechanisms of Resistance to PARP Inhibitors.
    • Piombino C, Cortesi L.
    • Cancers (Basel). 2022 Jun 5;14(11):2804. doi: 10.3390/cancers14112804.
    • PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    • Nicum S, Blagden SP.
    • Clin Cancer Res. 2022 Jun 1;28(11):2201-2203. doi: 10.1158/1078-0432.CCR-22-0442.
    • Commentary

    Related:

    Original research:

    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).

    • Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    • Gao Q, Zhu J, Zhao W, Huang Y, An R, Zheng H, Qu P, Wang L, Zhou Q, Wang D, Lou G, Wang J, Wang K, Low J, Kong B, Rozita AM, Sen LC, Yin R, Xie X, Liu J, Sun W, Su J, Zhang C, Zang R, Ma D.
    • Clin Cancer Res. 2022 Jun 1;28(11):2278-2285. doi: 10.1158/1078-0432.CCR-21-3023.

    Related:

    Commentary:

    PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.

    • SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    • Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr.
    • J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471.
    • Brain metastases in patients with ovarian cancer.
    • Limon D, Shachar E, Wolf I, Adar L, Peleg Hasson S, Ferro L, Safra T.
    • Acta Oncol. 2022 Jun;61(6):757-763. doi: 10.1080/0284186X.2022.2066985. Epub 2022 Apr 29.
    • The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    • Francis KE, Kim SI, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade-Lauraine E, Kim JW, Lee CK.
    • Ann Oncol. 2022 Jun;33(6):593-601. doi: 10.1016/j.annonc.2022.02.222. Epub 2022 Feb 24.

    Related:

    •• Commentary:

    For ovarian cancer PARPi maintenance therapy: more is better, right?

    •• Research news: Reassuring Data: Olaparib Dose Reductions Have Minimal Effect. (Medscape Oncology)

    •• Research news: Study: More is not better: PARP dose can be safely reduced for people with ovarian cancer. (FORCE. XRAY.)

    • Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    • Smith M, Pothuri B.
    • Curr Treat Options Oncol. 2022 Jun;23(6):887-903. doi: 10.1007/s11864-022-00938-4. Epub 2022 Apr 12.
    • Review
    • Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.
    • Skrzypczyk-Ostaszewicz A.
    • Drugs Today (Barc). 2022 Jun;58(6):299-309. doi: 10.1358/dot.2022.58.6.3389001.
    • Review
    • PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    • Luo L, Keyomarsi K.
    • Expert Opin Investig Drugs. 2022 Jun;31(6):607-631. doi: 10.1080/13543784.2022.2067527. Epub 2022 May 3.
    • Review
    • Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
    • Vergote I, Denys H, Altintas S, Kerger J, Baurain JF, Bours V, Henry S, Van de Vijver K, Lambrechts D, Gennigens C.
    • Facts Views Vis Obgyn. 2022 Jun;14(2):111-120. doi: 10.52054/FVVO.14.2.024.
    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17.
    • Review
    • Evolution in adjuvant treatment of ovarian carcinoma [Évolution des traitements adjuvants des cancers de l'ovaire].
    • Pautier P.
    • Rev Prat. 2022 Jun;72(6):633-637. French.
    • Olaparib for ovarian cancer: a single-institution, multi-site qualitative study.
    • Martin NA, Hanna M, Ehret C, Asiedu G, Jatoi A.
    • Support Care Cancer. 2022 Jun;30(6):4807-4812. doi: 10.1007/s00520-022-06879-w. Epub 2022 Feb 11.
    • Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    • Rabban JT, Chen LM, Devine WP.
    • Surg Pathol Clin. 2022 Jun;15(2):219-234. doi: 10.1016/j.path.2022.02.003. Epub 2022 May 18.
    • Review
    • Is there a "Low Risk" Patient Population in Advanced Epithelial Ovarian Cancer?: A Critical Analysis.
    • Chambers LM, O'Malley DM, Coleman RL, Herzog TJ.
    • Am J Obstet Gynecol. 2022 May 28:S0002-9378(22)00412-4. doi: 10.1016/j.ajog.2022.05.047. Epub ahead of print.
    • Commentary
    • Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report.
    • Valls ML, Kase AM, Patel R, Wang B, Aggarwal R, Colon-Otero G.
    • Gynecol Oncol Rep. 2022 May 25;41:101010. doi: 10.1016/j.gore.2022.101010.
    • Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance.
    • Kyo S, Kanno K, Takakura M, Yamashita H, Ishikawa M, Ishibashi T, Sato S, Nakayama K.
    • Cancers (Basel). 2022 May 19;14(10):2504. doi: 10.3390/cancers14102504.
    • Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    • Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD.
    • Gynecol Oncol. 2022 May 19:S0090-8258(22)00305-5. doi: 10.1016/j.ygyno.2022.05.005. Epub ahead of print.
    • Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    • Wen H, Feng Z, Ma Y, Liu R, Ou Q, Guo Q, Shen Y, Wu X, Shao Y, Bao H, Wu X.
    • BMC Cancer. 2022 May 16;22(1):550. doi: 10.1186/s12885-022-09602-4.
    • Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.
    • Witjes VM, Braspenning JCC, Hoogerbrugge N, Smolders YHCM, Hermkens DMA, Mourits MJE, Ligtenberg MJL, Ausems MGEM, de Hullu JA.
    • Fam Cancer. 2022 May 16. doi: 10.1007/s10689-022-00294-0. Epub ahead of print.
    • The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    • Skelin M, Šarcevic D, Lešin Gacina D, Mucalo I, Dilber I, Javor E.
    • J Chemother. 2022 May 13:1-8. doi: 10.1080/1120009X.2022.2073161. Epub ahead of print.
    • Meta-Analysis
    • Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective.
    • Rose PG.
    • Cancer Drug Resist. 2022 May 12;5(2):415-423. doi: 10.20517/cdr.2022.01.
    • Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer.
    • Flynn MJ, Ledermann JA.
    • Cancer Drug Resist. 2022 May 12;5(2):424-435. doi: 10.20517/cdr.2022.13.
    • BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.
    • Ergasti R, Marchetti C, Tudisco R, Iervolino A, Naldini A, Oliva R, Inzani F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 May 3;32(5):639-645. doi: 10.1136/ijgc-2021-003116.
    • A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    • Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaarde B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, Swisher EM, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN-8282 study team.
    • Cancer Chemother Pharmacol. 2022 May;89(5):721-735. doi: 10.1007/s00280-022-04430-6. Epub 2022 Apr 18.
    • A Review of MutSa and its Absence in Mismatch Repair Related Ovarian Carcinomas.
    • Hayes A, Jaman A, Johnson E, Rausch M.
    • FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R4038.
    • Conference abstract. Review
    • PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    • Miller RE, El-Shakankery KH, Lee JY.
    • J Gynecol Oncol. 2022 May;33(3):e44. doi: 10.3802/jgo.2022.33.e44. Epub 2022 Mar 8.
    • The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population.
    • Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, Behl S, Arcand SL, Nayar P, Spiegelman D, Gravel S, Mes-Masson AM, Provencher D, Foulkes WD, El Haffaf Z, Rouleau G, Bouchard L, Greenwood CMT, Masson JY, Ragoussis J, Tonin PN.
    • Cancers (Basel). 2022 Apr 30;14(9):2251. doi: 10.3390/cancers14092251.
    • Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature.
    • Zhang Z, Xu M, Sakandar A, Du X, He H, He W, Li D, Wen Q.
    • Front Oncol. 2022 Apr 29;12:873198. doi: 10.3389/fonc.2022.873198.
    • Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer.
    • Gou R, Horikawa N, Kosaka K.
    • BMJ Case Rep. 2022 Apr 20;15(4):e249177. doi: 10.1136/bcr-2022-249177.
    • Case report
    • Improving ovarian cancer treatment decision using a novel risk predictive tool.
    • Xu Z, Song J, Cao L, Rong Z, Zhang W, He J, Li K, Hou Y.
    • Aging (Albany NY). 2022 Apr 19;14(8):3464-3483. doi: 10.18632/aging.204023. Epub 2022 Apr 19.
    • A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients.
    • Lee CS, Hernandez J, Liang C, Leung A, Stefanov DG, Cheng K, John V.
    • J Pharm Pract. 2022 Apr 19:8971900221088793. doi: 10.1177/08971900221088793. Epub ahead of print.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
    • Weber-Lassalle K, Ernst C, Reuss A, Möllenhoff K, Baumann K, Jackisch C, Hauke J, Dietrich D, Borde J, Park-Simon TW, Hanker L, Prieske K, Schmidt S, Weber-Lassalle N, Pohl-Rescigno E, Kommoss S, Marmé F, Heitz F, Stingl JC, Schmutzler RK, Harter P, Hahnen E.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):565-570. doi: 10.1093/jnci/djab231.

    Related:

    Commentary:

    Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies.

    • Predicting Response to Anthracyclines in Ovarian Cancer.
    • Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N.
    • Int J Environ Res Public Health. 2022 Apr 2;19(7):4260. doi: 10.3390/ijerph19074260.
    • The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
    • Anastasia A, Dellavedova G, Ramos-Montoya A, James N, Chiorino G, Russo M, Baakza H, Wilson J, Ghilardi C, Cadogan EB, Giavazzi R, Bani MR.
    • Mol Cancer Ther. 2022 Apr 1;21(4):555-567. doi: 10.1158/1535-7163.MCT-21-0420.
    • The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
    • Murphy AD, Morgan RD, Clamp AR, Jayson GC.
    • Br J Cancer. 2022 Apr;126(6):851-864. doi: 10.1038/s41416-021-01605-5. Epub 2021 Oct 29.
    • Review
    • Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
    • Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI.
    • Br J Cancer. 2022 Apr;126(7):1027-1036. doi: 10.1038/s41416-021-01664-8. Epub 2021 Dec 9.
    • Immunotherapy for ovarian cancer.
    • Porter R, Matulonis UA.
    • Clin Adv Hematol Oncol. 2022 Apr;20(4):240-253.
    • An update on the safety of olaparib for treating ovarian cancer.
    • Cottrell K, Clark CL, Penson RT.
    • Expert Opin Drug Saf. 2022 Apr;21(4):447-451. doi: 10.1080/14740338.2022.2047176. Epub 2022 Mar 15.
    • Review
    • Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    • Vanderstichele A, Loverix L, Busschaert P, Van Nieuwenhuysen E, Han SN, Concin N, Callewaert T, Olbrecht S, Salihi R, Berteloot P, Neven P, Lambrechts D, Van Gorp T, Vergote I.
    • Gynecol Oncol. 2022 Apr;165(1):14-22. doi: 10.1016/j.ygyno.2022.01.034. Epub 2022 Feb 14.
    • Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    • Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E.
    • Gynecol Oncol. 2022 Apr;165(1):40-48. doi: 10.1016/j.ygyno.2022.01.024. Epub 2022 Jan 31.
    • Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    • Wagar MK, Mojdehbakhsh RP, Godecker A, Rice LW, Barroilhet L.
    • Gynecol Oncol. 2022 Apr;165(1):49-52. doi: 10.1016/j.ygyno.2022.01.032. Epub 2022 Feb 8.
    • Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    • Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim JW, Kim BG, Lee JY.
    • Gynecol Oncol. 2022 Apr;165(1):97-104. doi: 10.1016/j.ygyno.2022.02.002. Epub 2022 Feb 10.
    • Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience.
    • Moubarak M, Harter P, Ataseven B, Traut A, Welz J, Baert T, Heitz F.
    • Gynecol Oncol Rep. 2022 Feb 2 [eCollection 2022 Apr];40:100939. doi: 10.1016/j.gore.2022.100939.
    • Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
    • Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM.
    • Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14.

    Related:

    Commentary:

    Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial.

    Letter, Comment:

    Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations.

    Reply:

    Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply.

    • Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.
    • Liu J, Yin R, Wu L, Zhu J, Lou G, Wu X, Zhou Q, Gao Y, Kong B, Lu X, Wang J, Chen Y, Cheng Y, Wang Y, Lu W, Li W, Ma X, Hsu K.
    • Asia Pac J Clin Oncol. 2022 Mar 31. doi: 10.1111/ajco.13753. Epub ahead of print.
    • The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
    • Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, Cormio G, Maiello E.
    • Int J Mol Sci. 2022 Mar 31;23(7):3871. doi: 10.3390/ijms23073871.
    • Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    • Suh YJ, Lee B, Kim K, Jeong Y, Choi HY, Hwang SO, Kim YB.
    • BMC Cancer. 2022 Mar 30;22(1):346. doi: 10.1186/s12885-022-09455-x.
    • Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.
    • Harbin LM, Gallion HH, Allison DB, Kolesar JM.
    • Diagnostics (Basel). 2022 Mar 29;12(4):842. doi: 10.3390/diagnostics12040842.
    • Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future-Five-Years' Single-Institution Experience of 762 Consecutive Patients.
    • Fumagalli C, Betella I, Rappa A, di Giminiani M, Gaiano M, De Vitis LA, Zambetti B, Vacirca D, Multinu F, Venetis K, Colombo N, Barberis M, Guerini Rocco E.
    • Cancers (Basel). 2022 Mar 23;14(7):1638. doi: 10.3390/cancers14071638.
    • Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study.
    • Zhou D, Liu J, Liu R, Li H, Huang Y, Ma D, Hong L, Gao Q.
    • Front Oncol. 2022 Mar 23;12:852772. doi: 10.3389/fonc.2022.852772.

    Related:

    Identifier: NCT04507841: Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer. (ClinicalTrials.gov)

    • Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
    • Li Y, Nie Y, Guo H, Guo H, Ha C, Li Y.
    • Front Oncol. 2022 Mar 18;12:847085. doi: 10.3389/fonc.2022.847085.
    • U.S. FDA Drug Approvals for Gynecological Malignancies - A Decade in Review.
    • Arora S, Narayan P, Ison G, Berman T, Suzman DL, Wedam S, Prowell TM, Ghosh S, Philip R, Osgood CL, Gao JJ, Shah M, Krol D, Wahby S, Royce M, Brus C, Bloomquist EW, Fiero MH, Tang S, Pazdur R, Ibrahim A, Amiri-Kordestani L, Beaver JA.
    • Clin Cancer Res. 2022 Mar 15;28(6):1058-1071. doi: 10.1158/1078-0432.CCR-21-2599.
    • BRCA1 Mutation: An Insidious Enemy with Multiple Facets….
    • Godin P, Duhoux FP, Mazzeo F, Rojas M, Bollue E, François A, Galant C, Coulie J, Coyette M, Lentini A, Deswisen Y, Perlepe V, Fellah L, Leconte I, Berlière M.
    • Case Rep Oncol. 2022 Mar 14;15(1):238-244. doi: 10.1159/000521840.
    • PARP Inhibitors Resistance: Mechanisms and Perspectives.
    • Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D.
    • Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420.
    • Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing.
    • Stegel V, Blatnik A, Škof E, Dragoš VŠ, Krajc M, Gregoric B, Škerl P, Strojnik K, Klancar G, Banjac M, Žgajnar J, Ravnik M, Novakovic S.
    • Cancers (Basel). 2022 Mar 10;14(6):1434. doi: 10.3390/cancers14061434.
    • Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer.
    • Wei Q, Chen DS, Liu YH.
    • Front Oncol. 2022 Mar 10;12:853211. doi: 10.3389/fonc.2022.853211.
    • Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review.
    • Fujitsuka S, Horikawa N, Yoshida T, Yu S, Kuroda R, Tsuji M, Umemiya M, Gou R, Inayama Y, Tani H, Kosaka K.
    • Case Rep Oncol. 2022 Mar 3;15(1):156-162. doi: 10.1159/000522153.
    • Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • Lorusso D, Guy H, Samyshkin Y, Hawkes C, Estenson K, Coleman RL.
    • Cancers (Basel). 2022 Mar 2;14(5):1285. doi: 10.3390/cancers14051285.
    • Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer.
    • Chen Q, Li X, Zhang Z, Wu T.
    • Front Oncol. 2022 Mar 1;12:858826. doi: 10.3389/fonc.2022.858826.
    • European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
    • Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Ausems MGEM, Büttner R, Lambrechts D; European experts’ consensus group.
    • Ann Oncol. 2022 Mar;33(3):276-287. doi: 10.1016/j.annonc.2021.11.013. Epub 2021 Dec 1.

    Related:

    Commentary:

    Homologous recombination deficiency testing in first-line ovarian cancer.

    • Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    • Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E.
    • Gynecol Oncol. 2022 Mar;164(3):498-504. doi: 10.1016/j.ygyno.2021.12.025. Epub 2022 Jan 19.
    • A review on mechanisms of resistance to PARP inhibitors.
    • Desai C, Pathak A, Limaye S, Maniar V, Joshi A.
    • Indian J Cancer. 2022 Mar;59(Supplement):S119-S129. doi: 10.4103/ijc.IJC_53_21.
    • A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    • Park J, Lim MC, Lee JK, Jeong DH, Kim SI, Choi MC, Kim BG, Lee JY.
    • J Gynecol Oncol. 2022 Mar;33(2):e12. doi: 10.3802/jgo.2022.33.e12. Epub 2021 Dec 6.
    • Major clinical research advances in gynecologic cancer in 2021.
    • Park JY, Lee JY, Lee YY, Shim SH, Suh DH, Kim JW.
    • J Gynecol Oncol. 2022 Mar;33(2):e43. doi: 10.3802/jgo.2022.33.e43.
    • The BRCA Gene in Epithelial Ovarian Cancer.
    • Sánchez-Lorenzo L, Salas-Benito D, Villamayor J, Patiño-García A, González-Martín A.
    • Cancers (Basel). 2022 Feb 27;14(5):1235. doi: 10.3390/cancers14051235.
    • Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer.
    • Maity J, Horibata S, Zurcher G, Lee JM.
    • Cancers (Basel). 2022 Feb 26;14(5):1219. doi: 10.3390/cancers14051219.
    • Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report.
    • Qian B, Leng W, Yan Z, Lu J, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Feb 25;12:778545. doi: 10.3389/fonc.2022.778545.
    • Sophia Genetics, AstraZeneca Team on In-House HRD Testing in Ovarian Cancer.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2022 Feb 24.
    • Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives.
    • Musacchio L, Cicala CM, Salutari V, Camarda F, Carbone MV, Ghizzoni V, Giudice E, Nero C, Perri MT, Ricci C, Tronconi F, Scambia G, Lorusso D.
    • Front Oncol. 2022 Feb 23;12:831612. doi: 10.3389/fonc.2022.831612.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 21;14(4):1098. doi: 10.3390/cancers14041098.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J.
    • Cochrane Database Syst Rev. 2022 Feb 16;2:CD007929. doi: 10.1002/14651858.CD007929.pub4.
    • Review
    • Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
    • Wu X, Zhu J, Wang J, Lin Z, Yin R, Sun W, Zhou Q, Zhang S, Wang D, Shi H, Gao Y, Huang Y, Li G, Wang X, Cheng Y, Lou G, Gao Q, Wang L, Du X, Pan M, Mu X, Li L, Li M, Mu S, Kong B.
    • Clin Cancer Res. 2022 Feb 15;28(4):653-661. doi: 10.1158/1078-0432.CCR-21-1186.
    • Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
    • Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A, Juan O, Romero I, Lopez-Guerrero JA.
    • Cancers (Basel). 2022 Feb 12;14(4):915. doi: 10.3390/cancers14040915.
    • Sister Mary Joseph nodule as cutaneous manifestations of metastatic ovarian cancer: A case report and review of the literature.
    • Nie X, Chen X, Jiang Y, Zhong Y, Chen T, Cheng W.
    • Medicine (Baltimore). 2022 Feb 11;101(6):e28712. doi: 10.1097/MD.0000000000028712.
    • Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.
    • Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI.
    • JCO Precis Oncol. [2022 Feb 9];6:e2100456. doi: 10.1200/PO.21.00456.
    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    • Perez JM, Twigg CAI, Guan W, Thomas SN.
    • J Am Soc Mass Spectrom. 2022 Feb 2;33(2):242-250. doi: 10.1021/jasms.1c00215. Epub 2021 Dec 27.
    • Inibidores da PARP: do mecanismo de ação à prática clínica [PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
    • Branco C, Paredes J.
    • Acta Med Port. 2022 Feb 1;35(2):135-143. Portuguese. doi: 10.20344/amp.13870. Epub 2022 Feb 1.
    • Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.
    • Imyanitov EN, Iyevleva AG.
    • Cancer Lett. 2022 Feb 1;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.
    • Review
    • Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.
    • Paffenholz SV, Salvagno C, Ho YJ, Limjoco M, Baslan T, Tian S, Kulick A, de Stanchina E, Wilkinson JE, Barriga FM, Zamarin D, Cubillos-Ruiz JR, Leibold J, Lowe SW.
    • Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2117754119. doi: 10.1073/pnas.2117754119.

    Related:

    Commentary:

    Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.

    • 11 ESMO 2021 breakthroughs: practicing oncologist's perceptions on data presentation.
    • van Halteren HK, Tan A, Pellegrino B, Brasiuniene B, Bennouna J, Cunquero-Tomás AJ, Strijbos M; ESMO Practicing Oncologists Working Group.
    • ESMO Open. 2022 Feb;7(1):100376. doi: 10.1016/j.esmoop.2021.100376. Epub 2022 Jan 17.
    • Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    • Stone RL, Cambron-Mellott MJ, Beusterien K, Maculaitis MC, Ritz S, Mulvihill E, Monberg M, Szamreta EA, Amin S, McLaurin K.
    • Future Oncol. 2022 Feb;18(4):491-503. doi: 10.2217/fon-2021-0567. Epub 2021 Dec 8.
    • Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    • Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL.
    • Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11.

    Related:

    Commentary:

    Testing for homologous recombination deficiency - does it provide new insights for the use of veliparib?

    Podcast:

    February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?

    • Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    • Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL.
    • Gynecol Oncol. 2022 Feb;164(2):278-287. doi: 10.1016/j.ygyno.2021.12.012. Epub 2021 Dec 18.
    • Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    • Moya-Alarcón C, González-Domínguez A, Ivanova-Markova Y, Gimeno-Ballester V, Barretina-Ginesta MP, Pérez-Fidalgo JA, Redondo A.
    • Gynecol Oncol. 2022 Feb;164(2):406-414. doi: 10.1016/j.ygyno.2021.11.011. Epub 2021 Nov 26.
    • Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    • Ha HI, Park EY, Eoh KJ, Lee YJ, Seo SS, Kang S, Park SY, Lim MC.
    • Gynecol Oncol. 2022 Feb;164(2):415-420. doi: 10.1016/j.ygyno.2021.12.013. Epub 2021 Dec 17.
    • PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.
    • Kraya AA, Maxwell KN, Eiva MA, Wubbenhorst B, Pluta J, Feldman M, Nayak A, Powell DJ Jr, Domchek SM, Vonderheide RH, Nathanson KL.
    • JCO Precis Oncol. 2022 Feb;6:e2100159. doi: 10.1200/PO.21.00159.
    • Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.
    • Pirš B, Škof E, Smrkolj V, Smrkolj Š.
    • Cancers (Basel). 2022 Jan 27;14(3):631. doi: 10.3390/cancers14030631.
    • Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.
    • Lodewijk I, Bernardini A, Suárez-Cabrera C, Bernal E, Sánchez R, Garcia JL, Rojas K, Morales L, Wang S, Han X, Dueñas M, Paramio JM, Manso L.
    • NPJ Precis Oncol. 2022 Jan 27;6(1):7. doi: 10.1038/s41698-021-00247-3.
    • FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations.
    • Rosa K.
    • OncLive. 2022 Jan 25.

    Related:

    News release: Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations. (Senhwa Biosciences. Accessed 2022 Oct 5.)

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov . Accessed 2022 Oct 5.)

    • Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes.
    • Custódio N, Savisaar R, Carvalho C, Bak-Gordon P, Ribeiro MI, Tavares J, Nunes PB, Peixoto A, Pinto C, Escudeiro C, Teixeira MR, Carmo-Fonseca M.
    • Biomedicines. 2022 Jan 18;10(2):199. doi: 10.3390/biomedicines10020199.
    • Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
    • Kanakkanthara A, Hou X, Ekstrom TL, Zanfagnin V, Huehls AM, Kelly RL, Ding H, Larson MC, Vasmatzis G, Oberg AL, Kaufmann SH, Mansfield AS, Weroha SJ, Karnitz LM.
    • Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. Epub 2021 Nov 22.
    • Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report.
    • Cortesi L, Venturelli M, Barbieri E, Baldessari C, Bardasi C, Coccia E, Baglio F, Rimini M, Greco S, Napolitano M, Pipitone S, Dominici M.
    • Ther Adv Chronic Dis. 2022 Jan 13;13:20406223211063023. doi: 10.1177/20406223211063023.
    • Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Pagkali A, Mamais I, Michalinos A, Agouridis AP.
    • Curr Oncol. 2022 Jan 12;29(1):321-336. doi: 10.3390/curroncol29010029.
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
    • Ni J, Guo W, Zhao Q, Cheng X, Xu X, Zhou R, Gu H, Chen C, Chen X.
    • Front Oncol. 2022 Jan 6;11:746571. doi: 10.3389/fonc.2021.746571.
    • Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study.
    • Fu M, Jin C, Feng S, Jia Z, Nie L, Zhang Y, Peng J, Wang X, Bu H, Kong B.
    • Front Oncol. 2022 Jan 6;11:810099. doi: 10.3389/fonc.2021.810099.
    • Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    • Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, Barrett JC, Hodgson D.
    • BMC Cancer. 2022 Jan 3;22(1):13. doi: 10.1186/s12885-021-09082-y.
    • A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
    • Park SJ, Chang SJ, Suh DH, Kong TW, Song H, Kim TH, Kim JW, Kim HS, Lee SJ.
    • BMC Cancer. 2022 Jan 3;22(1):28. doi: 10.1186/s12885-021-09138-z.
    • Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
    • Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, Lee JY, Choi JK.
    • Cancer Res. 2022 Jan 1;82(1):142-154. doi: 10.1158/0008-5472.CAN-21-2023. Epub 2021 Oct 28.
    • Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    • Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G.
    • Br J Cancer. 2022 Jan;126(1):120-128. doi: 10.1038/s41416-021-01609-1. Epub 2021 Nov 3.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • As Maintenance Therapy, Olaparib's Benefits Continue.
    • [No author given]
    • Cancer Discov. 2022 Jan;12(1):6-7. doi: 10.1158/2159-8290.CD-NB2021-0401. Epub 2021 Nov 19.
    • Research news

    Related:

    Original research:

    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

    • Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    • Trédan O, Provansal M, Abdeddaim C, Lardy-Cleaud A, Hardy-Bessard AC, Kalbacher E, Floquet A, Venat-Bouvet L, Lortholary A, Pop O, Frenel JS, Cancel M, Largillier R, Louvet C, You B, Zannetti A, Anota A, Treilleux I, Pissaloux D, Houlier A, Savoye AM, Mouret-Reynier MA, Meunier J, Levaché CB, Brocard F, Ray-Coquard I.
    • Gynecol Oncol. 2022 Jan;164(1):18-26. doi: 10.1016/j.ygyno.2021.09.024. Epub 2021 Oct 23.
    • Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients.
    • Moya-Alarcón C, Piera G, Callejo Á, Gascó A.
    • J Comp Eff Res. 2022 Jan;11(1):13-27. doi: 10.2217/cer-2021-0135. Epub 2021 Oct 26.
    • Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
    • Farrell R, Burling M, Lee YC, Pather S, Robledo K, Mercieca-Bebber R, Stockler M; HyNOVA Protocol Steering Committee.
    • J Gynecol Oncol. 2022 Jan;33(1):e1. doi: 10.3802/jgo.2022.33.e1. Epub 2021 Oct 18.
    • Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
    • Ghirardi V, De Felice F, D'Indinosante M, Bernardini F, Giudice MT, Fagotti A, Scambia G.
    • Cancer Treat Res Commun. 2022;31:100518. doi: 10.1016/j.ctarc.2022.100518. Epub 2022 Jan 14.
    • CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.
    • Manganaro L, Celli V, Viggiani V, Berardelli E, Granato T, Tartaglione S, Farina A, Catalano C, Angeloni A, Anastasi E.
    • Tumour Biol. 2022;44(1):171-185. doi: 10.3233/TUB-211557.
    • Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.
    • Garrido MP, Fredes AN, Lobos-González L, Valenzuela-Valderrama M, Vera DB, Romero C.
    • Biomedicines. 2021 Dec 31;10(1):77. doi: 10.3390/biomedicines10010077.
    • DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
    • Stefanou DT, Souliotis VL, Zakopoulou R, Liontos M, Bamias A.
    • Biomedicines. 2021 Dec 31;10(1):82. doi: 10.3390/biomedicines10010082.
    • Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.
    • Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, Naboulsi DJ, Liang V, Qu Y, Plummer JT, Gayther SA, Orsulic S, Karlan BY, Svendsen CN.
    • Cell Rep. 2021 Dec 28;37(13):110146. doi: 10.1016/j.celrep.2021.110146.

    Related:

    Research news: Researchers Create Organoids that Model BRCA-Positive Ovarian Cancer. (Clinical OMICs)

    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    • Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, Burney I.
    • BMC Cancer. 2021 Dec 20;21(1):1350. doi: 10.1186/s12885-021-09094-8.
    • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
    • Zhang M, Ma SC, Tan JL, Wang J, Bai X, Dong ZY, Zhang QX.
    • Front Oncol. 2021 Dec 16;11:772604. doi: 10.3389/fonc.2021.772604.
    • Perspectives on PARP Inhibitor Combinations for Ovarian Cancer.
    • Bonadio RC, Estevez-Diz MDP.
    • Front Oncol. 2021 Dec 15;11:754524. doi: 10.3389/fonc.2021.754524.
    • Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
    • Noh JJ, Kim MK, Choi MC, Lee JW, Park H, Jung SG, Joo WD, Song SH, Lee C.
    • Cancer Res Treat. 2021 Dec 13. doi: 10.4143/crt.2021.828. Epub ahead of print.
    • Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study).
    • Liontos M, Timotheadou E, Papadopoulos EI, Zafeiriou Z, Lampropoulou DI, Aravantinos G, Mavroudis D, Christodoulou C, Nikolaidi A, Somarakis A, Papadimitriou C, Papandreou C, Bamias A.
    • Curr Oncol. 2021 Dec 10;28(6):5266-5277. doi: 10.3390/curroncol28060440.
    • Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
    • Zhang JQ, Zhao BB, Wang MM, Li L.
    • Front Oncol. 2021 Dec 6;11:603591. doi: 10.3389/fonc.2021.603591.
    • Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
    • Scotto G, Borella F, Turinetto M, Tuninetti V, Valsecchi AA, Giannone G, Cosma S, Benedetto C, Valabrega G.
    • Cells. 2021 Dec 3;10(12):3408. doi: 10.3390/cells10123408.
    • Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
    • Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN.
    • Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18.
    • Mise à jour 2021 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire épithélial de haut grade: Updated 2021 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in epithelial high grade ovarian cancer.
    • Joly F, Ray-Coquard I.
    • Bull Cancer. 2021 Dec;108(9S1):S1-S4. French. doi: 10.1016/S0007-4551(21)00581-6.
    • Guideline, [Article in French]
    • Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
    • Selle F, Alexandre J, Prulhière K, Kalbacher E, Ray-Coquard I, Leary A; pour le groupe GINECO.
    • Bull Cancer. 2021 Dec;108(9S1):S5-S12. doi: 10.1016/S0007-4551(21)00582-8.
    • Guideline
    • Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
    • Pautier P, Motte-Rouge T, Lécuru F, Classe JM, Ferron G, Floquet A, Kurtz JE, Freyer G, Hardy-Bessard AC.
    • Bull Cancer. 2021 Dec;108(9S1):S22-S32. doi: 10.1016/S0007-4551(21)00584-1.
    • Guideline
    • Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    • Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA.
    • Gynecol Oncol. 2021 Dec;163(3):490-497. doi: 10.1016/j.ygyno.2021.08.030. Epub 2021 Sep 30.
    • Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    • Azzalini E, Barbazza R, Stanta G, Giorda G, Bortot L, Bartoletti M, Puglisi F, Canzonieri V, Bonin S.
    • Gynecol Oncol. 2021 Dec;163(3):498-505. doi: 10.1016/j.ygyno.2021.09.012. Epub 2021 Oct 1.
    • Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    • Hodgson DR, Brown JS, Dearden SP, Lai Z, Elks CE, Milenkova T, Dougherty BA, Lanchbury JS, Perry M, Timms KM, Harrington EA, Barrett JC, Leary A, Pujade-Lauraine E.
    • Gynecol Oncol. 2021 Dec;163(3):563-568. doi: 10.1016/j.ygyno.2021.10.002. Epub 2021 Nov 4.
    • ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
    • Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS.
    • Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30.
    • Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    • Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P.
    • Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26. Erratum in: Lancet Oncol. 2021 Dec;22(12):e539.

    Related:

    Research news:

    As Maintenance Therapy, Olaparib's Benefits Continue.

    • BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
    • Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B, Pantel K, Joosse SA.
    • Mol Oncol. 2021 Dec;15(12):3615-3625. doi: 10.1002/1878-0261.13108. Epub 2021 Oct 12.
    • Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
    • Klotz DM, Link T, Wimberger P, Kuhlmann JD.
    • Mol Oncol. 2021 Dec;15(12):3626-3638. doi: 10.1002/1878-0261.12949. Epub 2021 Apr 2.
    • Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
    • Dias MP, Moser SC, Ganesan S, Jonkers J.
    • Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
    • Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
    • Xu Q, Li Z.
    • Front Pharmacol. 2021 Nov 29;12:743073. doi: 10.3389/fphar.2021.743073.
    • Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    • Wang H, Wu M, Liu H, Zhou H, Zhao Y, Geng Y, Jiang B, Zhang K, Zhang B, Han Z, Du X.
    • Front Oncol. 2021 Nov 24;11:785102. doi: 10.3389/fonc.2021.785102.
    • Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
    • DiSilvestro P, Colombo N, Harter P, González-Martín A, Ray-Coquard I, Coleman RL.
    • Cancers (Basel). 2021 Nov 17;13(22):5756. doi: 10.3390/cancers13225756.
    • Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    • Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A.
    • Genome Med. 2021 Nov 9;13(1):174. doi: 10.1186/s13073-021-00976-x.
    • Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer.
    • Gao L, Chen R, Li T, Li L, Zheng Q.
    • Front Pharmacol. 2021 Nov 8;12:771836. doi: 10.3389/fphar.2021.771836.
    • VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
    • Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, Hattersley MM, Arnold S, Ramos-Montoya A, Williamson SC, Galbiati A, Urosevic J, Leo E, Cavallaro U, Ghilardi C, Barry ST, Bani MR, Giavazzi R.
    • J Hematol Oncol. 2021 Nov 6;14(1):186. doi: 10.1186/s13045-021-01196-x.
    • PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    • Rose PG, Yao M, Chambers LM, Mahdi H, DeBernardo R, Michener CM, AlHilli M, Ricci S, Vargas R.
    • Anticancer Drugs. 2021 Nov 1;32(10):1086-1092. doi: 10.1097/CAD.0000000000001219.
    • Heightened Sensitivity of Germline BRCA Mutant Patients Treated With Concurrent or Adjuvant PARP Inhibition and Radiotherapy for Brain Metastases.
    • Santos P, Imber BS, Lapen K, Pike LRG, Moss N, Seidman AD, Beal K.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):e605. doi: 10.1016/j.ijrobp.2021.07.1614.
    • Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    • Moore KN, Pothuri B.
    • Cancer J. 2021 Nov-Dec 01;27(6):432-440. doi: 10.1097/PPO.0000000000000558.
    • Review
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.
    • Pham MM, Hinchcliff E, Avila M, Westin SN.
    • Cancer J. 2021 Nov-Dec 01;27(6):491-500. doi: 10.1097/PPO.0000000000000562.
    • Review
    • Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.
    • Miller RE.
    • Cancer J. 2021 Nov-Dec 01;27(6):506-510. doi: 10.1097/PPO.0000000000000565.
    • Review
    • The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
    • You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, Pignata S, Pujade-Lauraine E.
    • Cancer Treat Rev. 2021 Nov;100:102294. doi: 10.1016/j.ctrv.2021.102294. Epub 2021 Sep 15.
    • Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
    • Matsuo K, Klar M, Mohrbacher AF, Roman LD, Wright JD.
    • Eur J Cancer. 2021 Nov;157:59-62. doi: 10.1016/j.ejca.2021.08.016. Epub 2021 Sep 3.
    • Letter
    • Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    • Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P.
    • Eur J Cancer. 2021 Nov;157:415-423. doi: 10.1016/j.ejca.2021.08.023. Epub 2021 Sep 28.
    • Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.
    • Westin SN, Louie-Gao M, Gupta D, Thaker PH.
    • Future Oncol. 2021 Nov;17(32):4263-4274. doi: 10.2217/fon-2021-0018. Epub 2021 Aug 11.
    • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    • Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F.
    • Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 5.
    • Adherence to PARP inhibitor therapy among women with ovarian cancer.
    • Moss HA, Chen L, Hershman DL, Davidson B, Wright JD.
    • Gynecol Oncol. 2021 Nov;163(2):262-268. doi: 10.1016/j.ygyno.2021.08.025. Epub 2021 Sep 9.
    • Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    • Saccardi C, Zovato S, Spagnol G, Bonaldo G, Marchetti M, Alessandrini L, Tognazzo S, Guerriero A, Vitagliano A, Laganà AS, Noventa M.
    • Gynecol Oncol. 2021 Nov;163(2):364-370. doi: 10.1016/j.ygyno.2021.08.021. Epub 2021 Aug 28.
    • Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer.
    • Navitski A, Al-Rawi DH, Liu Y, Rubinstein MM, Friedman CF, Rampal RK, Mandelker DL, Cadoo K, O'Cearbhaill RE.
    • Gynecol Oncol Rep. 2021 Oct 5;38:100873. doi: 10.1016/j.gore.2021.100873. eCollection 2021 Nov.
    • Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020.
    • Obermair A, Beale P, Scott CL, Beshay V, Kichenadasse G, Simcock B, Nicklin J, Lee YC, Cohen P, Meniawy T.
    • J Gynecol Oncol. 2021 Nov;32(6):e95. doi: 10.3802/jgo.2021.32.e95.
    • Synthetic Lethality in Ovarian Cancer.
    • Chandrasekaran A, Elias KM.
    • Mol Cancer Ther. 2021 Nov;20(11):2117-2128. doi: 10.1158/1535-7163.MCT-21-0500. Epub 2021 Sep 13.
    • Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
    • Paik J.
    • Target Oncol. 2021 Nov;16(6):847-856. doi: 10.1007/s11523-021-00842-1. Epub 2021 Oct 8.
    • Review
    • Homologous recombination proficiency in ovarian and breast cancer patients.
    • Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J.
    • BMC Cancer. 2021 Oct 28;21(1):1154. doi: 10.1186/s12885-021-08863-9.
    • BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials.
    • Li S, Tao L, Dai H, Gong X, Zhuo Y, Xiang H, Zhao Y, Gao Q, Deng L.
    • Front Oncol. 2021 Oct 28;11:718871. doi: 10.3389/fonc.2021.718871.
    • PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
    • Barcellini A, Loap P, Murata K, Villa R, Kirova Y, Okonogi N, Orlandi E.
    • Cancers (Basel). 2021 Oct 27;13(21):5380. doi: 10.3390/cancers13215380.
    • The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    • Tao M, Wu X.
    • J Exp Clin Cancer Res. 2021 Oct 26;40(1):338. doi: 10.1186/s13046-021-02139-7.
    • PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    • Mehta P, Bothra SJ.
    • Adv Genet. 2021;108:35-80. doi: 10.1016/bs.adgen.2021.08.002. Epub 2021 Oct 23.
    • Review. Book chapter
    • Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer.
    • Drouin L, Guani B, Balaya V, Azaïs H, Betrian S, Bolze PA, Dabi Y, Kerbage Y, Sanson C, Zaccarini F, Mathevet P, Lécuru F, Guyon F, Akladios C, Bendifallah S, Deluche E, On Behalf Of The Sfog Campus Young Of French Society Of Gynecological Oncology.
    • J Clin Med. 2021 Oct 21;10(21):4829. doi: 10.3390/jcm10214829.
    • Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing.
    • Wessman S, Fuentes BB, Törngren T, Kvist A, Kokaraki G, Menkens H, Hjerpe E, Hugo Y, Petta TB, Borg Å, Carlson JW.
    • Cancers (Basel). 2021 Oct 19;13(20):5240. doi: 10.3390/cancers13205240.
    • Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.
    • Wong OGW, Li J, Cheung ANY.
    • Front Oncol. 2021 Oct 19;11:666815. doi: 10.3389/fonc.2021.666815.
    • A Retrospective Cross-Sectional Cohort Trial Assessing the Prevalence of MTHFR Polymorphisms and the Influence of Diet on Platinum Resistance in Ovarian Cancer Patients.
    • Phillips-Chavez C, Coward J, Watson M, Schloss J.
    • Cancers (Basel). 2021 Oct 18;13(20):5215. doi: 10.3390/cancers13205215.
    • Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    • Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, Spierings DCJ, Schlecht H, Burghel GJ, Foijer F, Desai S, McGrail JC, Taylor SS.
    • J Exp Clin Cancer Res. 2021 Oct 16;40(1):323. doi: 10.1186/s13046-021-02124-0.
    • Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
    • Sztupinszki Z, Diossy M, Börcsök J, Prosz A, Cornelius N, Kjeldsen MK, Mirza MR, Szallasi Z.
    • Clin Cancer Res. 2021 Oct 15;27(20):5681-5687. doi: 10.1158/1078-0432.CCR-21-0981. Epub 2021 Aug 11.
    • Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
    • Chiang YC, Lin PH, Cheng WF.
    • Front Oncol. 2021 Oct 14;11:675972. doi: 10.3389/fonc.2021.675972.
    • Ovarian Cancer With Breast Metastasis and Two Pathogenic Variants of BRCA1 Gene.
    • Kowsarnia S, Javadi N.
    • Cureus. 2021 Oct 11;13(10):e18691. doi: 10.7759/cureus.18691.
    • Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
    • Tang YH, Lin CY, Lai CH.
    • Genes (Basel). 2021 Oct 9;12(10):1593. doi: 10.3390/genes12101593.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
    • Zavarikina TM, Khokhlova SV, Tyulyandina AS, Khabas GN, Asaturova AV, Nosova YV, Brenner PK, Kapralova MA, Khodirev DS, Stenina MB.
    • Bull Exp Biol Med. 2021 Oct;171(6):755-759. doi: 10.1007/s10517-021-05310-4. Epub 2021 Oct 28.
    • PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    • Wethington SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, Karlan BY, Fader AN, Dowdy SC.
    • Gynecol Oncol. 2021 Oct;163(1):11-13. doi: 10.1016/j.ygyno.2021.08.002. Epub 2021 Aug 12.
    • Commentary
    • Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    • Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
    • Gynecol Oncol. 2021 Oct;163(1):41-49. doi: 10.1016/j.ygyno.2021.07.016. Epub 2021 Aug 2.
    • Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
    • Liu J, Hawkes C, Walder L, Spalding C, Travers K, Maiese EM, Hurteau J.
    • J Manag Care Spec Pharm. 2021 Oct;27(10):1377-1387. doi: 10.18553/jmcp.2021.27.10.1377.
    • Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status.
    • Rolfe M, Gegeckas C, Turner S, Orr JW Jr.
    • J Oncol Pharm Pract. 2021 Oct;27(7):1704-1709. doi: 10.1177/1078155220967988. Epub 2020 Oct 25.
    • Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    • Barbosa A, Pinto P, Peixoto A, Guerra J, Pinheiro M, Santos C, Pinto C, Escudeiro C, Bartosch C, Santos R, Brandão A, Silva J, Teixeira MR.
    • Front Oncol. 2021 Sep 30;11:754094. doi: 10.3389/fonc.2021.754094.
    • Towards a CRISPeR understanding of homologous recombination with high-throughput functional genomics.
    • Hayward SB, Ciccia A.
    • Curr Opin Genet Dev. 2021 Sep 25;71:171-181. doi: 10.1016/j.gde.2021.08.006. Epub ahead of print.
    • Review
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
    • Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL.
    • Cancer Med. 2021 Sep 21. doi: 10.1002/cam4.4260. Epub ahead of print.
    • Role of adjuvant and post-surgical treatment in gynaecological cancer.
    • Ngu SF, Ngan HY, Chan KK.
    • Best Pract Res Clin Obstet Gynaecol. 2021 Sep 15:S1521-6934(21)00124-3. doi: 10.1016/j.bpobgyn.2021.09.001. Epub ahead of print.
    • Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells.
    • Chirshev E, Suzuki T, Wang H, Nguyen A, Hojo N, Sanderman L, Mirshahidi S, Ioffe YJ, Unternaehrer JJ.
    • Cancers (Basel). 2021 Sep 15;13(18):4617. doi: 10.3390/cancers13184617.
    • Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
    • Saravi S, Alizzi Z, Tosi S, Hall M, Karteris E.
    • Cells. 2021 Sep 15;10(9):2434. doi: 10.3390/cells10092434.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
    • Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP.
    • JCO Precis Oncol. 2021 Sep 7;5:PO.20.00439. doi: 10.1200/PO.20.00439.
    • Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor.
    • Ni J, Cheng X, Zhou R, Zhao Q, Xu X, Guo W, Gu H, Chen C, Chen X.
    • Front Oncol. 2021 Sep 6;11:724620. doi: 10.3389/fonc.2021.724620.
    • Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
    • Lai J, Tong C, Chien JR.
    • Anticancer Res. 2021 Sep;41(9):4417-4422. doi: 10.21873/anticanres.15248.
    • Case report
    • Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    • Rasmussen M, Lim K, Rambech E, Andersen MH, Svane IM, Andersen O, Jensen LH, Nilbert M, Therkildsen C.
    • Gynecol Oncol. 2021 Sep;162(3):686-693. doi: 10.1016/j.ygyno.2021.07.001. Epub 2021 Jul 16.
    • Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases.
    • Gallego A, Garrido D, Yébenes L, Mendiola M, Castelo B, Redondo A.
    • Int J Gynecol Cancer. 2021 Sep;31(9):1292-1296. doi: 10.1136/ijgc-2020-002225.
    • Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
    • Fujiwara K, Fujiwara H, Yoshida H, Satoh T, Yonemori K, Nagao S, Matsumoto T, Kobayashi H, Bourgeois H, Harter P, Mosconi AM, Vazquez IP, Reinthaller A, Fujita T, Rowe P, Pujade-Lauraine E, Ray-Coquard I.
    • J Gynecol Oncol. 2021 Sep;32(5):e82. doi: 10.3802/jgo.2021.32.e82.
    • Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
    • Mani C, Tripathi K, Chaudhary S, Somasagara RR, Rocconi RP, Crasto C, Reedy M, Athar M, Palle K.
    • Neoplasia. 2021 Sep;23(9):1002-1015. doi: 10.1016/j.neo.2021.06.010. Epub 2021 Aug 8.
    • Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
    • Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators, Serra V, Waring P, Lim E, Caldon CE.
    • NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x.
    • Cytotoxic and targeted therapy for BRCA1/2-driven cancers.
    • Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):36. doi: 10.1186/s13053-021-00193-y.
    • Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.
    • Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B.
    • Curr Oncol. 2021 Aug 24;28(5):3227-3239. doi: 10.3390/curroncol28050280.
    • The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer.
    • Lan H, Yuan J, Zeng D, Liu C, Guo X, Yong J, Zeng X, Xiao S.
    • Front Genet. 2021 Aug 20;12:693259. doi: 10.3389/fgene.2021.693259.
    • Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay.
    • Nikoleousakos N, Dalezis P, Polonifi A, Geromichalou EG, Sagredou S, Alifieris CE, Deligiorgi MV, Sarli V, Trafalis DT.
    • Biomedicines. 2021 Aug 17;9(8):1028. doi: 10.3390/biomedicines9081028.
    • Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study.
    • Velev M, Puszkiel A, Blanchet B, de Percin S, Delanoy N, Medioni J, Gervais C, Balakirouchenane D, Khoudour N, Pautier P, Leary A, Ajgal Z, Hirsch L, Goldwasser F, Alexandre J, Beinse G.
    • Pharmaceuticals (Basel). 2021 Aug 16;14(8):804. doi: 10.3390/ph14080804.
    • Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Ren N, Zhang L, Yu J, Guan S, Dai X, Sun L, Ying M.
    • Front Oncol. 2021 Aug 13;11:638295. doi: 10.3389/fonc.2021.638295.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
    • Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    • Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, Morrow M, Berek JS, Hofer TP, Katz SJ, Ward KC.
    • J Natl Cancer Inst. 2021 Aug 9:djab151. doi: 10.1093/jnci/djab151. Epub ahead of print.
    • PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
    • Dickson KA, Xie T, Evenhuis C, Ma Y, Marsh DJ.
    • Int J Mol Sci. 2021 Aug 7;22(16):8506. doi: 10.3390/ijms22168506.
    • Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
    • Kim SI, Lee JW, Kim K, Lee M, Yoo J, Choi MC, Hwangbo S, Kwak YH, Lee JM, Shin SJ, Shim SH, Kim MK.
    • J Gynecol Oncol. 2021 Aug 5. doi: 10.3802/jgo.2021.32.e90. Epub ahead of print.
    • Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2021 Aug 3.
    • Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    • Manning-Geist BL, Chi DS, Long Roche K, Zivanovic O, Sonoda Y, Gardner GJ, O'Cearbhaill RE, Abu-Rustum NR, Leitao MM Jr.
    • Gynecol Oncol. 2021 Aug;162(2):345-352. doi: 10.1016/j.ygyno.2021.05.015. Epub 2021 May 25.
    • Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    • Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF.
    • Gynecol Oncol. 2021 Aug;162(2):482-495. doi: 10.1016/j.ygyno.2021.05.018. Epub 2021 Jun 3.
    • Review
    • Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
    • Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L.
    • Gynecol Oncol. 2021 Aug;162(2):496-505. doi: 10.1016/j.ygyno.2021.05.012. Epub 2021 May 19.
    • Meta-Analysis
    • Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence.
    • Nakanishi K, Yamada T, Ishikawa G, Suzuki S.
    • Front Oncol. 2021 Jul 29;11:697952. doi: 10.3389/fonc.2021.697952.
    • Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    • Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Eftekhariyan Ghamsari MR, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Cancer Study AO, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.
    • Cancer Res. 2021 Jul 28:canres.0774.2021. doi: 10.1158/0008-5472.CAN-21-0774. Epub ahead of print.
    • Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    • Perez-Fidalgo JA, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A.
    • ESMO Open. 2021 Jul 27;6(4):100212. doi: 10.1016/j.esmoop.2021.100212. Epub ahead of print.
    • Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
    • Imyanitov E, Sokolenko A.
    • World J Clin Oncol. 2021 Jul 24;12(7):544-556. doi: 10.5306/wjco.v12.i7.544.
    • Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    • Marchetti C, Rosati A, De Felice F, Boccia SM, Vertechy L, Pavone M, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00587-4. doi: 10.1016/j.ygyno.2021.07.025. Epub ahead of print.
    • Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    • Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.
    • Exp Cell Res. 2021 Jul 21:112742. doi: 10.1016/j.yexcr.2021.112742. Epub ahead of print.
    • Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma.
    • Conteduca V, Scarpi E, Farolfi A, Brighi N, Rossi L, Gurioli G, Lolli C, Schepisi G, Bleve S, Gianni C, Virga A, Altavilla A, Burgio SL, Menna C, De Giorgi U.
    • Front Oncol. 2021 Jul 21;11:716467. doi: 10.3389/fonc.2021.716467.
    • Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    • Moss HA, Perhanidis JA, Havrilesky LJ, Secord AA.
    • Gynecol Oncol. 2021 Jul 20:S0090-8258(21)00588-6. doi: 10.1016/j.ygyno.2021.07.026. Epub ahead of print.
    • Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
    • Tjokrowidjaja A, Friedlander M, Lord SJ, Asher R, Rodrigues M, Ledermann JA, Matulonis UA, Oza AM, Bruchim I, Huzarski T, Gourley C, Harter P, Vergote I, Scott CL, Meier W, Shapira-Frommer R, Milenkova T, Pujade-Lauraine E, Gebski V, Lee CK.
    • Eur J Cancer. 2021 Jul 19;154:190-200. doi: 10.1016/j.ejca.2021.06.024. Epub ahead of print.
    • Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    • De Nonneville A, Zemmour C, Frank S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye AM, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Sabatier R.
    • Gynecol Oncol. 2021 Jul 19:S0090-8258(21)00581-3. doi: 10.1016/j.ygyno.2021.07.019. Epub ahead of print.
    • Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    • Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee.
    • Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19.
    • Meta-Analysis
    • PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
    • Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Oaknin A, Lorusso D, Ray-Coquard I.
    • Cancer Treat Rev. 2021 Jul 15;99:102255. doi: 10.1016/j.ctrv.2021.102255. Epub ahead of print.
    • Review
    • Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
    • Raimundo L, Calheiros J, Saraiva L.
    • Cancers (Basel). 2021 Jul 9;13(14):3438. doi: 10.3390/cancers13143438.
    • Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer.
    • Leung JH, Lang HC, Wang SY, Lo HF, Chan AL.
    • Expert Rev Pharmacoecon Outcomes Res. 2021 Jul 9. doi: 10.1080/14737167.2021.1954506. Epub ahead of print.
    • Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
    • Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH.
    • NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028.
    • Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
    • Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA.
    • Am J Obstet Gynecol. 2021 Jul;225(1):68.e1-68.e11. doi: 10.1016/j.ajog.2021.01.029. Epub 2021 Feb 4.
    • Multimodal Treatment of Primary Advanced Ovarian Cancer.
    • Friedrich M, Friedrich D, Kraft C, Rogmans C.
    • Anticancer Res. 2021 Jul;41(7):3253-3260. doi: 10.21873/anticanres.15111. Epub 2021 Jul 5.
    • Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
    • Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L.
    • Br J Cancer. 2021 Jul;125(1):7-14. doi: 10.1038/s41416-021-01295-z. Epub 2021 Mar 25.
    • Commentary, Review
    • Pamiparib: First Approval.
    • Markham A.
    • Drugs. 2021 Jul;81(11):1343-1348. doi: 10.1007/s40265-021-01552-8.
    • Review
    • BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    • Royfman R, Whiteley E, Noe O, Morand S, Creeden J, Stanbery L, Hamouda D, Nemunaitis J.
    • Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
    • Review
    • Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan.
    • Hsu CC, Pan YB, Lai CH, Chang TC, Yang LY, Chou HH.
    • Taiwan J Obstet Gynecol. 2021 Jul;60(4):634-638. doi: 10.1016/j.tjog.2021.05.010.
    • Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer.
    • Sanders BE, Ku L, Walker P, Bitler BG.
    • Technol Cancer Res Treat. 2021 Jan-Dec [First Published June 25, 2021.];20:15330338211027917. doi: 10.1177/15330338211027917.
    • The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
    • Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel E.
    • Cancers (Basel). 2021 Jun 23;13(13):3136. doi: 10.3390/cancers13133136.
    • Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway.
    • Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B.
    • Biomedicines. 2021 Jun 22;9(7):706. doi: 10.3390/biomedicines9070706.
    • An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    • Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.
    • Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.
    • History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.
    • Muggia F, Bonetti A.
    • Cancer Drug Resist. 2021 Jun 19;4(2):453-462. doi: 10.20517/cdr.2020.116.
    • Ovarian Cancer: Biomarkers and Targeted Therapy.
    • Radu MR, Pradatu A, Duica F, Micu R, Cretoiu SM, Suciu N, Cretoiu D, Varlas VN, Radoi VE.
    • Biomedicines. 2021 Jun 18;9(6):693. doi: 10.3390/biomedicines9060693.
    • Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.
    • Shen J, Liu T, Bei Q, Xu S.
    • Front Oncol. 2021 Jun 17;11:685065. doi: 10.3389/fonc.2021.685065.
    • Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
    • Dunn C, Gately L, Gibbs P.
    • JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1904. Epub ahead of print.
    • Letter, Comment

    Related:

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Original research:

    Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

    • Phase 1 Combination Study of the CHK1 inhibitor prexasertib, and the PARP inhibitor olaparib, in high-grade serous ovarian cancer and other solid tumors.
    • Do K, Kochupurakkal BS, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2021 Jun 15:clincanres.1279.2021. doi: 10.1158/1078-0432.CCR-21-1279. Epub ahead of print.
    • Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.
    • Romero I, López-Guerrero JA, Pignata S.
    • Expert Rev Anticancer Ther. 2021 Jun 15. doi: 10.1080/14737140.2021.1941890. Epub ahead of print.
    • Review
    • Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial).
    • Marchetti C, Tudisco R, Salutari V, Pietragalla A, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2021 Jun 15:ijgc-2021-002727. doi: 10.1136/ijgc-2021-002727. Epub ahead of print.
    • Fuzuloparib: First Approval.
    • Lee A.
    • Drugs. 2021 Jun 12. doi: 10.1007/s40265-021-01541-x. Epub ahead of print.
    • Review
    • Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
    • Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Goble S, Coleman RL, Ledermann JA.
    • Int J Gynecol Cancer. 2021 Jun 8:ijgc-2020-002240. doi: 10.1136/ijgc-2020-002240. Epub ahead of print.
    • Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    • Aghajanian C, Bookman MA, Fleming GF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL.
    • Gynecol Oncol. 2021 Jun 7:S0090-8258(21)00437-6. doi: 10.1016/j.ygyno.2021.05.031. Epub ahead of print.
    • Advances in the Treatment of Platinum Resistant Epithelial Ovarian Cancer: an update on standard and experimental therapies.
    • Leung SOA, Konstantinopoulos PA.
    • Expert Opin Investig Drugs. 2021 Jun 4. doi: 10.1080/13543784.2021.1939305. Epub ahead of print.
    • Review
    • Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    • Sokolenko AP, Gorodnova TV, Bizin IV, Kuligina ES, Kotiv KB, Romanko AA, Ermachenkova TI, Ivantsov AO, Preobrazhenskaya EV, Sokolova TN, Broyde RV, Imyanitov EN.
    • Cancer Chemother Pharmacol. 2021 Jun 2. doi: 10.1007/s00280-021-04301-6. Epub ahead of print.
    • Enhancing the sensitivity of ovarian cancer cells to olaparib via microRNA-20b-mediated cyclin D1 targeting.
    • Zhong Q, Xiong Y, Ling C, Qian Y, Zhao X, Yang H.
    • Exp Biol Med (Maywood). 2021 Jun;246(11):1297-1306. doi: 10.1177/1535370221994077.
    • Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
    • Le Saux O, Vanacker H, Guermazi F, Carbonnaux M, Roméo C, Larrouquère L, Trédan O, Ray-Coquard I.
    • Future Oncol. 2021 Jun;17(18):2291-2304. doi: 10.2217/fon-2021-0059. Epub 2021 Mar 17.
    • Review
    • Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
    • Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2021 Jun;161(3):653-659. doi: 10.1016/j.ygyno.2021.03.011. Epub 2021 Mar 15.
    • Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    • Zhang X, Devins K, Ko EM, Reyes MC, Simpkins F, Drapkin R, Schwartz LE, Yoon JY.
    • Gynecol Oncol. 2021 Jun;161(3):762-768. doi: 10.1016/j.ygyno.2021.03.019. Epub 2021 Mar 24.
    • PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
    • Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y, Wang J.
    • Redox Biol. 2021 Jun;42:101928. doi: 10.1016/j.redox.2021.101928. Epub 2021 Mar 5.
    • The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    • Havrilesky LJ, Scott AL, Davidson BA, Secord AA, Yang JC, Johnson FR, Gonzalez JM, Reed SD.
    • Gynecol Oncol. 2021 May 27:S0090-8258(21)00428-5. doi: 10.1016/j.ygyno.2021.05.022. Epub ahead of print.
    • Breast Cancer Predisposition Genes and Synthetic Lethality.
    • Neiger HE, Siegler EL, Shi Y.
    • Int J Mol Sci. 2021 May 25;22(11):5614. doi: 10.3390/ijms22115614.
    • Precision medicine for hereditary tumors in gynecologic malignancies.
    • Sekine M, Enomoto T.
    • J Obstet Gynaecol Res. 2021 May 25. doi: 10.1111/jog.14861. Epub ahead of print.
    • Review
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Homologous recombination deficiency: cancer predispositions and treatment implications.
    • Toh MR, Ngeow J.
    • Oncologist. 2021 May 22. doi: 10.1002/onco.13829. Epub ahead of print.
    • Metronomic oral cyclophosphamide in relapsed ovarian cancer.
    • Spiliopoulou P, Hinsley S, McNeish IA, Roxburgh P, Glasspool R.
    • Int J Gynecol Cancer. 2021 May 20:ijgc-2021-002467. doi: 10.1136/ijgc-2021-002467. Epub ahead of print.
    • Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian).
    • Evrard C, Alexandre J.
    • Cancers (Basel). 2021 May 18;13(10):2434. doi: 10.3390/cancers13102434.
    • DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    • Min A, Lee KH, Im SA.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:159-179. doi: 10.1007/978-981-32-9620-6_8.
    • Review, eBook chapter
    • Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.
    • Paracchini L, D'Incalci M, Marchini S.
    • Cancers (Basel). 2021 May 14;13(10):2386. doi: 10.3390/cancers13102386.
    • MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer.
    • Bååth M, Jönsson JM, Westbom Fremer S, Martín de la Fuente L, Tran L, Malander S, Kannisto P, Måsbäck A, Honeth G, Hedenfalk I.
    • Genes (Basel). 2021 May 14;12(5):742. doi: 10.3390/genes12050742.
    • Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
    • Cecere SC, Musacchio L, Bartoletti M, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Naglieri E, Scollo P, Marchetti C, Raspagliesi F, Greggi S, Cinieri S, Bergamini A, Orditura M, Valabrega G, Scambia G, Martinelli F, De Matteis E, Cardalesi C, Loizzi V, Perniola G, Carella C, Scandurra G, Giannone G, Pignata S.
    • Int J Gynecol Cancer. 2021 May 14:ijgc-2020-002343. doi: 10.1136/ijgc-2020-002343. Epub ahead of print.
    • C/EBPß promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    • Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q.
    • Oncogene. 2021 May 8. doi: 10.1038/s41388-021-01788-4. Epub ahead of print.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
    • Blankenship L, Lyons YA, Dao Campi H, Valente PT, Barnes L, Kost ER.
    • Gynecol Oncol Rep. 2021 May 5;36:100772. doi: 10.1016/j.gore.2021.100772.
    • Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.
    • Zhou Z, Li M.
    • JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
    • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
    • Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA.
    • Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
    • An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.
    • Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, Yin R, Wu X, Yao S, Gu K, Zhang H, Li G, Pan H, Wu Q, An R, Yang X, Zhu Y, Wan X, Duan W, Xiong J, Guo H, Lou G, Wang J, Hu W, Zhang X, Meng Y, Zhang B, Wang Y, Wang Q, Wu L.
    • Clin Cancer Res. 2021 May 1;27(9):2452-2458. doi: 10.1158/1078-0432.CCR-20-3546. Epub 2021 Feb 8.
    • Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
    • Zhang R, Wang T, Lin J.
    • Anticancer Res. 2021 May;41(5):2277-2286. doi: 10.21873/anticanres.15003.
    • Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    • Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS.
    • Cancer Med. 2021 May;10(9):3045-3058. doi: 10.1002/cam4.3831. Epub 2021 Apr 3.
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. Erratum in: Eur J Cancer. 2021 Aug;153:274.
    • Meta-Analysis
    • Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
    • Della Corte L, Foreste V, Di Filippo C, Giampaolino P, Bifulco G.
    • Expert Opin Investig Drugs. 2021 May;30(5):543-554. doi: 10.1080/13543784.2021.1901882. Epub 2021 Mar 24.
    • Review
    • Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    • Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN.
    • Gynecol Oncol. 2021 May;161(2):512-515. doi: 10.1016/j.ygyno.2021.01.037. Epub 2021 Feb 17.
    • Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    • Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, Long Roche K, Chi DS, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D, Weigelt B.
    • Gynecol Oncol. 2021 May;161(2):545-552. doi: 10.1016/j.ygyno.2021.02.028. Epub 2021 Mar 3.
    • Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series.
    • Kasherman L, Garg S, Tchrakian N, Clarke B, Karakasis K, Kim RH, Stockley TL, Dhani N, Oza AM, Lheureux S.
    • Gynecol Oncol Rep. 2021 Feb 12;36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.
    • Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
    • Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P.
    • Lancet Oncol. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13.
    • Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    • Kaneko M.
    • Ann Pharmacother. 2021 Apr 29:10600280211013489. doi: 10.1177/10600280211013489. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 24;13(9):2057. doi: 10.3390/cancers13092057.
    • A Population Pharmacokinetic Meta-analysis of Veliparib, a PARP Inhibitor, Across Phase I/II/III Trials in Cancer Patients.
    • Stodtmann S, Nuthalapati S, Eckert D, Kasichayanula S, Joshi R, Bach BA, Mensing S, Menon R, Xiong H.
    • J Clin Pharmacol. 2021 Apr 24. doi: 10.1002/jcph.1875. Epub ahead of print.
    • The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
    • Demény MA, Virág L.
    • Cancers (Basel). 2021 Apr 23;13(9):2042. doi: 10.3390/cancers13092042.
    • Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    • Giannone G, Scotto G, Katsaros D, De Giorgi U, Farolfi A, Borella F, Cosma S, Ferrero A, Mangiacotti S, Villa M, Tuninetti V, Ghisoni E, Turinetto M, Mittica G, Gemmiti S, Zavallone L, Aglietta M, Pasini B, Di Maio M, Valabrega G.
    • Gynecol Oncol. 2021 Apr 22:S0090-8258(21)00328-0. doi: 10.1016/j.ygyno.2021.04.018. Epub ahead of print.
    • Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
    • Cho A, Park JY, Lee SW, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT.
    • Arch Gynecol Obstet. 2021 Apr 19. doi: 10.1007/s00404-021-06013-x. Epub ahead of print.
    • FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers.
    • Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM 3rd, Hickson I, Tatum NJ, Rakha EA, Madhusudan S.
    • Cancers (Basel). 2021 Apr 14;13(8):1866. doi: 10.3390/cancers13081866.
    • In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
    • Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES.
    • Sci Rep. 2021 Apr 13;11(1):8042. doi: 10.1038/s41598-021-87325-5.
    • Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
    • Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L.
    • Cancer Manag Res. 2021 Apr 8;13:3081-3100. doi: 10.2147/CMAR.S292992.
    • Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    • Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T.
    • Cancers (Basel). 2021 Apr 7;13(8):1769. doi: 10.3390/cancers13081769.
    • Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    • Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK.
    • Gynecol Oncol. 2021 Apr 7:S0090-8258(21)00272-9. doi: 10.1016/j.ygyno.2021.04.002. Epub ahead of print.
    • The dystonia gene THAP1 controls DNA double-strand break repair choice.
    • Shinoda K, Zong D, Callen E, Wu W, Dumitrache LC, Belinky F, Chari R, Wong N, Ishikawa M, Stanlie A, Multhaupt-Buell T, Sharma N, Ozelius L, Ehrlich M, McKinnon PJ, Nussenzweig A.
    • Mol Cell. 2021 Apr 6:S1097-2765(21)00229-X. doi: 10.1016/j.molcel.2021.03.034. Epub ahead of print.
    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Related:

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Press: Germline Testing: Variant in 1 in 6 Cases of Advanced Cancer. (Medscape Oncology)

    • PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
    • Agarwal A, Baghmar S, Dodagoudar C, Qureshi S, Khurana A, Vaibhav V, Kumar G.
    • JCO Glob Oncol. 2021 Apr;7:506-511. doi: 10.1200/GO.20.00269.
    • Molecular disruption of DNA polymerase ß for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    • Ali R, Alblihy A, Miligy IM, Alabdullah ML, Alsaleem M, Toss MS, Algethami M, Abdel-Fatah T, Moseley P, Chan S, Mongan NP, Narayan S, Rakha EA, Madhusudan S.
    • Oncogene. 2021 Apr;40(14):2496-2508. doi: 10.1038/s41388-021-01710-y. Epub 2021 Mar 5.
    • Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
    • Patel PS, Algouneh A, Hakem R.
    • Oncogene. 2021 Apr;40(17):3001-3014. doi: 10.1038/s41388-021-01744-2. Epub 2021 Mar 14.
    • Review
    • Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).
    • Gadducci A, Aletti GD, Landoni F, Lazzari R, Mangili G, Olivas P, Pignata S, Salutari V, Sartori E, Scambia G, Zannoni GF, Sabbatini R, Lorusso D.
    • Tumori. 2021 Apr;107(2):100-109. doi: 10.1177/0300891620966382. Epub 2020 Oct 26.
    • Guideline. Review
    • Long-Term Follow-Up of a Female Patient Treated with Olaparib-Hope for a Long Life without Relapse?
    • Kozlowski M, Nowak K, Cymbaluk-Ploska A.
    • Int J Environ Res Public Health. 2021 Mar 26;18(7):3430. doi: 10.3390/ijerph18073430.
    • Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    • Naqvi MF, Vo HH, Vining D, Tsimberidou AM.
    • Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538.
    • The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
    • Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, Filieri ME, Cottafavi L, Giovanardi F, Madrigali S, Civallero M, Marcheselli L, Marchi I, Domati F, Venturelli M, Barbieri E, Grandi G, Tagliafico E, Cortesi L.
    • Diagnostics (Basel). 2021 Mar 21;11(3):565. doi: 10.3390/diagnostics11030565.
    • Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    • Stok C, Kok YP, van den Tempel N, van Vugt MATM.
    • Nucleic Acids Res. 2021 Mar 21:gkab151. doi: 10.1093/nar/gkab151. Epub ahead of print.
    • Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    • Ewing A, Meynert A, Churchman M, Grimes G, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson MJ, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, Genomes Partnership TS, McMahon L, Matakidou A, Dougherty BA, March R, Barrett JC, McNeish IA, Biankin AV, Roxburgh P, Gourley C, Semple CA.
    • Clin Cancer Res. 2021 Mar 19:clincanres.CCR-20-4068-A.2020. doi: 10.1158/1078-0432.CCR-20-4068. Epub ahead of print.
    • Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom.
    • Akaev I, Rahimi S, Onifade O, Gardner FJE, Castells-Rufas D, Jones E, Acharige S, Yeoh CC.
    • Diagnostics (Basel). 2021 Mar 19;11(3):547. doi: 10.3390/diagnostics11030547.
    • Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    • Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ.
    • Gynecol Oncol. 2021 Mar 19:S0090-8258(21)00235-3. doi: 10.1016/j.ygyno.2021.03.015. Epub ahead of print.
    • NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund.
    • [No author given]
    • Precision Oncology News. Business & Policy. 2021 Mar 19.
    • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
    • Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators.
    • Lancet Oncol. 2021 Mar 18:S1470-2045(21)00073-5. doi: 10.1016/S1470-2045(21)00073-5. Epub ahead of print.
    • Serum Selenium Level Predicts 10-Year Survival after Breast Cancer.
    • Szwiec M, Marciniak W, Derkacz R, Huzarski T, Gronwald J, Cybulski C, Debniak T, Jakubowska A, Lener M, Falco M, Kladny J, Baszuk P, Duszynski J, Kotsopoulos J, Narod SA, Lubinski J.
    • Nutrients. 2021 Mar 16;13(3):953. doi: 10.3390/nu13030953.
    • Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
    • Nero C, Ciccarone F, Pietragalla A, Duranti S, Daniele G, Salutari V, Carbone MV, Scambia G, Lorusso D.
    • Cancers (Basel). 2021 Mar 15;13(6):1298. doi: 10.3390/cancers13061298.
    • PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
    • Shao F, Duan Y, Zhao Y, Li Y, Liu J, Zhang C, He S.
    • Aging (Albany NY). 2021 Mar 11;13(6):8975-8988. doi: 10.18632/aging.202724. Epub 2021 Mar 11.
    • Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
    • Li Y, Zhang X, Gao Y, Shang C, Yu B, Wang T, Su J, Huang C, Wu Y, Guo H, Ha C.
    • Front Oncol. 2021 Mar 5;10:625866. doi: 10.3389/fonc.2020.625866.
    • The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    • Baert T, Ferrero A, Sehouli J, O Donnell DM, González-Martín A, Joly F, van der Velden J, Blecharz P, Tan DSP, Querleu D, Colombo N, du Bois A, Ledermann JA.
    • Ann Oncol. 2021 Mar 3:S0923-7534(21)00155-1. doi: 10.1016/j.annonc.2021.02.015. Epub ahead of print.
    • Review
    • Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
    • Conte C, Fagotti A, Avesani G, Trombadori C, Federico A, D'Indinosante M, Giudice MT, Pelligra S, Lodoli C, Marchetti C, Ferrandina G, Scambia G, Gallotta V.
    • Ann Transl Med. 2021 Mar;9(6):510. doi: 10.21037/atm-20-4690.
    • LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
    • Chen L, Hou J, Zeng X, Guo Q, Deng M, Kloeber JA, Tu X, Zhao F, Wu Z, Huang J, Luo K, Kim W, Lou Z.
    • Clin Transl Med. 2021 Mar;11(3):e341. doi: 10.1002/ctm2.341.
    • Suprarenal lymphadenectomy with nephrectomy for refractory ovarian cancer.
    • Park SJ, Kim HS.
    • Gland Surg. 2021 Mar;10(3):1268-1270. doi: 10.21037/gs.2020.04.08.
    • Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    • Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, Swisher EM.
    • Gynecol Oncol. 2021 Mar;160(3):786-792. doi: 10.1016/j.ygyno.2020.12.007. Epub 2020 Dec 26.
    • Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    • Liang MI, Chen L, Hershman DL, Hillyer GC, Huh WK, Guyton A, Wright JD.
    • Gynecol Oncol. 2021 Mar;160(3):793-799. doi: 10.1016/j.ygyno.2020.12.015. Epub 2020 Dec 27.
    • Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer.
    • Brennan A, Brennan D, Rees M, Hickey M.
    • Int J Gynecol Cancer. 2021 Mar;31(3):352-359. doi: 10.1136/ijgc-2020-002032. Epub 2020 Oct 30.
    • Review
    • Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
    • Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T.
    • J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10.
    • Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.
    • Lu HY, Tai YJ, Chen YL, Chiang YC, Hsu HC, Cheng WF.
    • J Gynecol Oncol. 2021 Mar;32(2):e18. doi: 10.3802/jgo.2021.32.e18. Epub 2020 Dec 3.
    • Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
    • Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N.
    • J Gynecol Oncol. 2021 Mar;32(2):e21. doi: 10.3802/jgo.2021.32.e21. Epub 2021 Jan 6.
    • The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
    • Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, Satoh T, Hirashima Y, Matsumura N, Yokoyama Y, Kawana K, Kyo S, Aoki D, Katabuchi H.
    • J Gynecol Oncol. 2021 Mar;32(2):e49. doi: 10.3802/jgo.2021.32.e49.
    • Nouvelles AMMs : niraparib et olaparib en première ligne dans les cancers de l’ovaire [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
    • Delaye M, Rodrigues M.
    • Bull Cancer. 2021 Feb 25:S0007-4551(21)00038-2. French. doi: 10.1016/j.bulcan.2021.01.003. Epub ahead of print.
    • Letter, [Article in French]
    • Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    • How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS.
    • Cancers (Basel). 2021 Feb 24;13(5):946. doi: 10.3390/cancers13050946.
    • A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
    • Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA.
    • Sci Rep. 2021 Feb 24;11(1):4433. doi: 10.1038/s41598-021-82671-w.
    • Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    • Xu Y, Ding L, Tian Y, Bi M, Han N, Wang L.
    • Front Oncol. 2021 Feb 22;10:573801. doi: 10.3389/fonc.2020.573801.
    • BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
    • Salwa A, Ferraresi A, Chinthakindi M, Vallino L, Vidoni C, Dhanasekaran DN, Isidoro C.
    • Biomedicines. 2021 Feb 18;9(2):207. doi: 10.3390/biomedicines9020207.
    • Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer.
    • Cheng LJ, Wong G, Chay WY, Ngeow J, Tan Y, Soon SS, Aziz MIA, Pearce F, Ng K.
    • Expert Rev Pharmacoecon Outcomes Res. 2021 Feb 16. doi: 10.1080/14737167.2021.1890587. Epub ahead of print.
    • Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
    • Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM.
    • Clin Cancer Res. 2021 Feb 15;27(4):983-991. doi: 10.1158/1078-0432.CCR-20-3089. Epub 2020 Nov 30.
    • How to start niraparib in real-world Asian ovarian cancer patients?
    • Hong SH.
    • J Gynecol Oncol. 2021 Feb 8:e36. doi: 10.3802/jgo.2021.32.e36. Epub ahead of print.
    • A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
    • Geenen JJ, Dackus GM, Schouten PC, Pluim D, Marchetti S, Sonke GS, Józwiak K, Huitema AD, Beijnen JH, Schellens JH, Linn SC.
    • Int J Cancer. 2021 Feb 4. doi: 10.1002/ijc.33498. Epub ahead of print.
    • Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin.
    • Gorodnova TV, Sokolenko AP, Kotiv KB, Sokolova TN, Ivantsov AO, Guseynov KD, Nekrasova EA, Smirnova OA, Berlev IV, Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Feb 3;19(1):14. doi: 10.1186/s13053-021-00173-2.
    • Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    • Hinchcliff E, Chelariu-Raicu A, Westin SN.
    • Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):19-25. doi: 10.1097/GCO.0000000000000678.
    • Review
    • When in the treatment continuum to use PARP inhibition in ovarian cancer.
    • Mirza MR.
    • Clin Adv Hematol Oncol. 2021 Feb;19(2):84-86.
    • BRCA-2 (+) high-grade serous fallopian tube cancer diagnosed as an isolated breast mass by mammography.
    • Sobecki JN, Dryer KA, Mahajan AM, Spencer RJ.
    • Gynecol Oncol Rep. 2020 Dec 25;35:100690. doi: 10.1016/j.gore.2020.100690. eCollection 2021 Feb.
    • PARPi after PARPi in epithelial ovarian cancer.
    • Essel KG, Behbakht K, Lai T, Hand L, Evans E, Dvorak J, Ding K, Konecny G, Moore KN.
    • Gynecol Oncol Rep. 2021 Jan 11;35:100699. doi: 10.1016/j.gore.2021.100699. eCollection 2021 Feb.
    • DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
    • Pillay N, Brady R, Dey M, Morgan RD, Taylor SS.
    • Prog Biophys Mol Biol. 2021 Jan 29:S0079-6107(21)00005-5. doi: 10.1016/j.pbiomolbio.2021.01.004. Epub ahead of print.
    • Review
    • Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    • Kim DS, Camacho CV, Kraus WL.
    • Exp Mol Med. 2021 Jan 25. doi: 10.1038/s12276-021-00557-3. Epub ahead of print.
    • The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
    • Molnár S, Vida B, Beke L, Méhes G, Póka R.
    • Diagnostics (Basel). 2021 Jan 19;11(1):E144. doi: 10.3390/diagnostics11010144.
    • Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.
    • Tan DS, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC.
    • J Gynecol Oncol. 2021 Jan 18:e27. doi: 10.3802/jgo.2021.32.e27. Epub ahead of print.
    • Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    • Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G.
    • Drug Resist Updat. 2021 Jan 16:100744. doi: 10.1016/j.drup.2021.100744. Epub ahead of print.
    • Review
    • Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
    • Mansouri A, McGregor N, Dunn R, Dobbie S, Holmes J, Collins L, Nicum S.
    • BMJ Open. 2021 Jan 15;11(1):e041463. doi: 10.1136/bmjopen-2020-041463.
    • Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    • Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, Wu LY, Liu ZL, Gao YN, Wang DB, Lou G, Yang HY, Zhou Q, Kong BH, Huang Y, Chen LP, Li GL, An RF, Wang K, Zhang Y, Yan XJ, Lu X, Lu WG, Hao M, Wang L, Cui H, Chen QH, Abulizi G, Huang XH, Tian XF, Wen H, Zhang C, Hou JM, Mirza MR.
    • Ann Oncol. 2021 Jan 13:S0923-7534(21)00008-9. doi: 10.1016/j.annonc.2020.12.018. Epub ahead of print.
    • A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients.
    • Zhang Y, Shi X, Zhang J, Chen X, Zhang P, Liu A, Zhu T.
    • Sci Rep. 2021 Jan 11;11(1):387. doi: 10.1038/s41598-020-79694-0.
    • Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study.
    • Plotti F, Terranova C, Guzzo F, De Cicco Nardone C, Luvero D, Bartolone M, Dionisi C, Benvenuto D, Fabris S, Ciccozzi M, Di Donato V, Panici PB, Angioli R.
    • Biomedicines. 2021 Jan 8;9(1):E55. doi: 10.3390/biomedicines9010055.
    • The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
    • Goldsberry WN, Summerlin SS, Guyton A, Caddell B, Huh WK, Kim KH, Liang MI.
    • Gynecol Oncol. 2021 Jan 4:S0090-8258(20)34254-2. doi: 10.1016/j.ygyno.2020.12.039. Epub ahead of print.
    • Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
    • Todisco E, Gigli F, Mantiero M, Sammassimo S, Pastano R, Ronchini C, Parma G, Lapresa MT, Iori AP, Bertolini F, Corsini C, Gregato G, Poletti C, Colombo N, Tarella C.
    • Int J Cancer. 2021 Jan 1;148(1):170-177. doi: 10.1002/ijc.33269. Epub 2020 Sep 16.
    • Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
    • Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J.
    • J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406.
    • Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
    • Kurnit KC, Fleming GF, Lengyel E.
    • Obstet Gynecol. 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173.
    • Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer.
    • Xu B, Yin Y, Dong M, Song Y, Li W, Huang X, Wang T, He J, Mu X, Li L, Mu S, Zhang W, Li M.
    • Cancer Med. 2021 Jan;10(1):109-118. doi: 10.1002/cam4.3575. Epub 2020 Oct 31.
    • BRCA1/2 status and chemotherapy response score to tailor ovarian cancer surgery.
    • Ponzone R.
    • Crit Rev Oncol Hematol. 2021 Jan;157:103128. doi: 10.1016/j.critrevonc.2020.103128. Epub 2020 Oct 19.
    • Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
    • Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
    • Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.
    • Review
    • Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    • Michels J, Genestie C, Dunant A, Caron O, Lanoy E, Colomba E, Pommeret F, Rey A, Gouy S, Duvillard P, Teuff GL, Larue C, Savoye AM, Lhommé C, Leary A, Morice P, Pautier P.
    • Gynecol Oncol. 2021 Jan;160(1):77-82. doi: 10.1016/j.ygyno.2020.09.050. Epub 2020 Oct 12.
    • Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    • Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, Gao Y, Kong B, Lu X, Zhou Q, Wang Y, Chen Y, Lu W, Li W, Cheng Y, Liu J, Ma X, Zhang J.
    • Gynecol Oncol. 2021 Jan;160(1):175-181. doi: 10.1016/j.ygyno.2020.10.005. Epub 2020 Nov 27.
    • The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    • Haunschild CE, Tewari KS.
    • Gynecol Oncol. 2021 Jan;160(1):333-345. doi: 10.1016/j.ygyno.2020.09.043. Epub 2020 Oct 11.
    • Review
    • ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
    • Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S.
    • Int J Gynecol Cancer. 2021 Jan;31(1):134-138. doi: 10.1136/ijgc-2020-002073. Epub 2020 Oct 23.
    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • The Overtreatment and Cost Effectiveness of Primary versus Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).
    • Rose PG, Yao M, Chambers LM, Mei L, Le P.
    • Gynecol Obstet (Sunnyvale). 2021;11(9):570. Epub 2021 Oct 7.
    • To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
    • Rose PG, Chambers LM, Kuznicki M.
    • Gynecol Obstet (Sunnyvale). 2021;11(7):561. Epub 2021 Aug 3.
    • Adverse events of PARP inhibitors.
    • Romanová M, Klát J.
    • Ceska Gynekol. 2021 Winter;86(1):54-60. English. doi: 10.48095/cccg202154.
    • Review. [Article in Czech, English]
    • PARP inhibitors in ovarian cancer: an overview of the practice-changing trials.
    • Foo T, George A, Banerjee S.
    • Genes Chromosomes Cancer. 2020 Dec 31. doi: 10.1002/gcc.22935. Epub ahead of print.
    • Review
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    • Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I.
    • J Natl Cancer Inst. 2020 Dec 29:djaa193. doi: 10.1093/jnci/djaa193. Epub ahead of print.
    • Japanese Regulators Approve Lynparza for Ovarian, Prostate, Pancreatic Cancers.
    • [No author given]
    • Precision Oncology News. 2020 Dec 28.
    • The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.
    • Du ZH, Xia Y, Yang Q, Gao S.
    • Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289. [First Published December 24, 2020.]
    • MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/ß-catenin in serous ovarian cancers.
    • Sun Y, Wu J, Dong X, Zhang J, Meng C, Liu G.
    • Transl Oncol. 2020 Dec 21;14(2):100987. doi: 10.1016/j.tranon.2020.100987. Epub ahead of print.
    • BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    • Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9708. doi: 10.3390/ijms21249708.
    • PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    • Gralewska P, Gajek A, Marczak A, Mikula M, Ostrowski J, Sliwinska A, Rogalska A.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9715. doi: 10.3390/ijms21249715.
    • PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
    • Riad A, Gitto SB, Lee H, Winters HD, Martorano PM, Hsieh CJ, Xu K, Omran DK, Powell DJ Jr, Mach RH, Makvandi M.
    • Molecules. 2020 Dec 19;25(24):E6029. doi: 10.3390/molecules25246029.
    • Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review.
    • Tao M, Cheng J, Wu X.
    • Onco Targets Ther. 2020 Dec 18;13:12979-12986. doi: 10.2147/OTT.S281302.
    • Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    • Cho HY, Kim YB, Park WH, No JH.
    • Cancer Res Treat. 2020 Dec 16. doi: 10.4143/crt.2020.1013. Epub ahead of print.
    • A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    • Gonzalez Martin A, Sanchez Lorenzo L, Colombo N, dePont Christensen R, Heitz F, Meirovitz M, Selle F, van Gorp T, Alvarez N, Sanchez J, Marqués C.
    • Int J Gynecol Cancer. 2020 Dec 14:ijgc-3-001633. doi: 10.1136/ijgc-2020-001633. Epub ahead of print.
    • Non-invasive Technology Advances in Cancer-A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers.
    • Openshaw MR, McVeigh TP.
    • Front Digit Health. 2020 Dec 11;2:573010. doi: 10.3389/fdgth.2020.573010.
    • Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases.
    • Harada Y, Kubo M, Kai M, Yamada M, Zaguirre K, Ohgami T, Yahata H, Ohishi Y, Yamamoto H, Oda Y, Nakamura M.
    • Surg Case Rep. 2020 Dec 9;6(1):317. doi: 10.1186/s40792-020-01090-7.
    • A European, observational, prospective trial of trabectedin plus pegylated liposomal doxorubicin in patients with platinum-sensitive ovarian cancer.
    • Pignata S, Scambia G, Villanucci A, Naglieri E, Ibarbia MA, Brusa F, Bourgeois H, Sorio R, Casado A, Reichert D, Dopchie C, De Rivas B, de Sande LM.
    • Oncologist. 2020 Dec 8. doi: 10.1002/onco.13630. Epub ahead of print.
    • Editorial: Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment.
    • Grabenstetter A, Lazaro C, Turashvili G.
    • Front Oncol. 2020 Dec 2;10:618369. doi: 10.3389/fonc.2020.618369.
    • Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
    • Penn CA, Wong MS, Walsh CS.
    • JAMA Netw Open. 2020 Dec 1;3(12):e2028620. doi: 10.1001/jamanetworkopen.2020.28620.
    • Current practices on genetic testing in ovarian cancer.
    • Fostira F, Papadimitriou M, Papadimitriou C.
    • Ann Transl Med. 2020 Dec;8(24):1703. doi: 10.21037/atm-20-1422.
    • Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
    • Boussios S, Moschetta M, Karihtala P, Samartzis EP, Sheriff M, Pappas-Gogos G, Ozturk MA, Uccello M, Karathanasi A, Tringos M, Rassy E, Pavlidis N.
    • Ann Transl Med. 2020 Dec;8(24):1706. doi: 10.21037/atm.2020.03.156.
    • Treatment of Recurrent Epithelial Ovarian Cancer.
    • Claussen C, Rody A, Hanker L.
    • Geburtshilfe Frauenheilkd. 2020 Dec;80(12):1195-1204. doi: 10.1055/a-1128-0280. Epub 2020 Dec 3.
    • The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    • Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD.
    • Gynecol Oncol. 2020 Dec;159(3):850-859. doi: 10.1016/j.ygyno.2020.09.018. Epub 2020 Sep 23.
    • Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    • Ciccone MA, Adams CL, Bowen C, Thakur T, Ricker C, Culver JO, Maoz A, Melas M, Idos GE, Jeyasekharan AD, Matsuo K, Roman LD, Gruber SB, McDonnell KJ.
    • Gynecol Oncol. 2020 Dec;159(3):869-876. doi: 10.1016/j.ygyno.2020.09.040. Epub 2020 Oct 5.
    • Homologous recombination deficiency real-time clinical assays, ready or not?
    • Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A.
    • Gynecol Oncol. 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20.
    • Review
    • Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study.
    • Liu YL, Zhou QC, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner G, Broach V, O'Cearbhaill R, Konner JA, Grisham R, Aghajanian CA, Abu-Rustum NR, Tew W, Long Roche K.
    • Int J Gynecol Cancer. 2020 Dec;30(12):1915-1921. doi: 10.1136/ijgc-2020-001641. Epub 2020 Oct 26.
    • Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    • Zhang Z, Chang X, Zhang C, Zeng S, Liang M, Ma Z, Wang Z, Huang W, Shen Z.
    • J Enzyme Inhib Med Chem. 2020 Dec;35(1):1606-1615. doi: 10.1080/14756366.2020.1804382.
    • Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    • Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL.
    • Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.
    • Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
    • Wei Y, Ou T, Lu Y, Wu G, Long Y, Pan X, Yao D.
    • PeerJ. 2020 Nov 24;8:e10414. doi: 10.7717/peerj.10414.
    • Clinically Relevant Response to Treatment with Olaparib in a Patient with Refractory Multidrug-Resistant Ovarian Cancer and Central Nervous System Involvement: A Case Report.
    • Morales Vázquez F, López Basave HN, Méndez Herrera MDC, Peña González RR.
    • Am J Case Rep. 2020 Nov 23;21:e925990. doi: 10.12659/AJCR.925990.
    • Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.
    • Singh B, Yang S, Krishna A, Sridhar S.
    • Front Chem. 2020 Nov 23;8:594619. doi: 10.3389/fchem.2020.594619.
    • Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery.
    • Estati FL, Pirolli R, de Alencar VTL, Ribeiro ARG, Formiga MN, Torrezan GT, Carraro DM, Guimarães APG, Baiocchi G, da Costa AABA.
    • Ann Surg Oncol. 2020 Nov 21. doi: 10.1245/s10434-020-09366-w. Epub ahead of print.
    • Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
    • Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J.
    • Cancers (Basel). 2020 Nov 21;12(11):3468. doi: 10.3390/cancers12113468.
    • Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
    • Hao J, Liu Y, Zhang T, He J, Zhao H, An R, Xue Y.
    • Crit Rev Oncol Hematol. 2020 Nov 19;157:103145. doi: 10.1016/j.critrevonc.2020.103145. Epub ahead of print.
    • Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    • Sheta R, Bachvarova M, Plante M, Renaud MC, Sebastianelli A, Gregoire J, Navarro JM, Perez RB, Masson JY, Bachvarov D.
    • J Transl Med. 2020 Nov 19;18(1):439. doi: 10.1186/s12967-020-02613-4.
    • Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China.
    • [No author given]
    • Precision Oncology News. 2020 Nov 16.
    • Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    • Poort H, Fenton ATHR, Thompson E, Dinardo MM, Liu JF, Arch JJ, Wright AA.
    • Gynecol Oncol. 2020 Nov 12:S0090-8258(20)34056-7. doi: 10.1016/j.ygyno.2020.10.034. Epub ahead of print.
    • European Commission Green Lights Lynparza for Prostate, Ovarian Cancer Indications.
    • [No author given]
    • Precision Oncology News. 2020 Nov 5.
    • BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
    • Krais JJ, Johnson N.
    • Cancer Res. 2020 Nov 1;80(21):4601-4609. doi: 10.1158/0008-5472.CAN-20-1830. Epub 2020 Aug 3.
    • First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion.
    • Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, Ray-Coquard I.
    • ESMO Open. 2020 Nov;5(6):e001110. doi: 10.1136/esmoopen-2020-001110.
    • Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    • Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA.
    • Gynecol Oncol. 2020 Nov;159(2):442-448. doi: 10.1016/j.ygyno.2020.09.006. Epub 2020 Sep 25.

    Related:

    Identifier: NCT01847274: A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer. (ClinicalTrials.gov)

    • Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
    • Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, Dottino JA, Berchuck A, Moss HA.
    • Gynecol Oncol. 2020 Nov;159(2):483-490. doi: 10.1016/j.ygyno.2020.08.003. Epub 2020 Aug 27.
    • Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    • Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K.
    • Gynecol Oncol. 2020 Nov;159(2):491-497. doi: 10.1016/j.ygyno.2020.08.013. Epub 2020 Sep 18.
    • Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    • Eakin CM, Norton TJ, Monk BJ, Chase DM.
    • Gynecol Oncol. 2020 Nov;159(2):581-587. doi: 10.1016/j.ygyno.2020.08.016. Epub 2020 Sep 21.
    • Review
    • Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    • Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U.
    • Sci Rep. 2020 Oct 23;10(1):18190. doi: 10.1038/s41598-020-75316-x.
    • Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
    • [No author given]
    • GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.
    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review
    • Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
    • Stemmer A, Shafran I, Stemmer SM, Tsoref D.
    • Cancers (Basel). 2020 Oct 18;12(10):3026. doi: 10.3390/cancers12103026.
    • Newly diagnosed ovarian cancer: Which first-line treatment?
    • Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.
    • Cancer Treat Rev. 2020 Oct 9;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub ahead of print.
    • Review
    • Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.
    • Care M, McCuaig J, Clarke B, Grenier S, Kim RH, Rouzbahman M, Stickle N, Bernardini M, Stockley TL.
    • Mol Oncol. 2020 Oct 8. doi: 10.1002/1878-0261.12817. Epub ahead of print.
    • FDA Approval Summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer.
    • Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, Bloomquist E, Tang S, Gong Y, Sridhara R, Turcu FR, Chatterjee D, Saritas-Yildirim B, Ghosh S, Philip R, Pathak A, Gao JJ, Amiri-Kordestani L, Pazdur R, Beaver JA.
    • Oncologist. 2020 Oct 5. doi: 10.1002/onco.13551. Epub ahead of print.
    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review
    • Clinical assays for assessment of homologous recombination DNA repair deficiency.
    • Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF.
    • Gynecol Oncol. 2020 Oct 1:S0090-8258(20)33922-6. doi: 10.1016/j.ygyno.2020.09.029. Epub ahead of print.
    • Review
    • Advances in epithelial ovarian cancer.
    • Neesham D, Richards A, McGauran M.
    • Aust J Gen Pract. 2020 Oct;49(10):665-669.
    • Trabectedin for the therapy of ovarian cancer.
    • Evangelisti G, Barra F, D'Alessandro G, Tantari M, Stigliani S, Della Corte L, Bifulco G, Ferrero S.
    • Drugs Today (Barc). 2020 Oct;56(10):669-688. doi: 10.1358/dot.2020.56.10.3187001.
    • Review
    • Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study.
    • Lorusso D, Marchetti C, Conte C, Giudice E, Bolomini G, Vertechy L, Ceni V, Ditto A, Ferrandina G, Raspagliesi F, Scambia G, Fagotti A.
    • Gynecol Oncol. 2020 Oct;159(1):95-100. doi: 10.1016/j.ygyno.2020.07.022. Epub 2020 Jul 21.
    • The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    • Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL.
    • Gynecol Oncol. 2020 Oct;159(1):101-111. doi: 10.1016/j.ygyno.2020.05.045. Epub 2020 Aug 26.
    • PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.
    • Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G.
    • Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6.
    • The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
    • van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG.
    • Cancers (Basel). 2020 Sep 29;12(10):2805. doi: 10.3390/cancers12102805.
    • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    • Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR.
    • Ann Oncol. 2020 Sep 28:S0923-7534(20)42164-7. doi: 10.1016/j.annonc.2020.08.2102. Epub ahead of print.
    • Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
    • Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, Gladieff L, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, Pujade-Lauraine E.
    • Eur J Cancer. 2020 Sep 22;139:59-67. doi: 10.1016/j.ejca.2020.08.021. Epub ahead of print.
    • EMA Committee Recommends Approval of Lynparza, Avastin in Platinum-Sensitive Ovarian Cancer.
    • [No author given]
    • Precision Oncology News. 2020 Sep 21.
    • A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.
    • Pan Y, Jia LP, Liu Y, Han Y, Li Q, Zou Q, Zhang Z, Huang J, Deng Q.
    • J Ovarian Res. 2020 Sep 19;13(1):112. doi: 10.1186/s13048-020-00712-w.
    • Lynparza Maintenance Treatment in BRCA-Mutated Ovarian Cancer Shows Long-Term Benefit.
    • [No author given]
    • Precision Oncology News. 2020 Sep 18.
    • Olaparib treatment in older patients with ovarian cancer: need for 'real-world' data beyond clinical trials.
    • Liposits G, Wulff CN, Otland A, Fokdal LU.
    • Ecancermedicalscience. 2020 Sep 15;14:1104. doi: 10.3332/ecancer.2020.1104.
    • The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.
    • Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL.
    • Int J Gynecol Cancer. 2020 Sep 14:ijgc-2020-001789. doi: 10.1136/ijgc-2020-001789. Epub ahead of print.
    • Review
    • Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    • Gou R, Dong H, Lin B.
    • Life Sci. 2020 Sep 14:118434. doi: 10.1016/j.lfs.2020.118434. Epub ahead of print.
    • BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
    • Lui GYL, Shaw R, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C.
    • EBioMedicine. 2020 Sep 11;60:102988. doi: 10.1016/j.ebiom.2020.102988. Epub ahead of print.
    • Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
    • Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Sep 6:ijgc-2020-001556. doi: 10.1136/ijgc-2020-001556. Epub ahead of print.
    • Review
    • DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    • McMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM.
    • Int J Gynecol Cancer. 2020 Sep 2:ijgc-2020-001694. doi: 10.1136/ijgc-2020-001694. Epub ahead of print.
    • Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research.
    • Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger T, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez-Rodriguez L.
    • J Clin Med. 2020 Sep 1;9(9):E2830. doi: 10.3390/jcm9092830.
    • PARP inhibition as frontline therapy in ovarian cancer.
    • Moore KN, Pothuri B, Monk B, Coleman RL.
    • Clin Adv Hematol Oncol. 2020 Sep;18(9):550-556.
    • Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    • Gourley C, Miller RE, Hollis RL, Ledermann JA.
    • Curr Opin Oncol. 2020 Sep;32(5):442-450. doi: 10.1097/CCO.0000000000000660.
    • Review
    • Recent advancements in PARP inhibitors-based targeted cancer therapy.
    • Zhou P, Wang J, Mishail D, Wang CY.
    • Precis Clin Med. 2020 Sep;3(3):187-201. doi: 10.1093/pcmedi/pbaa030. Epub 2020 Aug 31.
    • Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
    • Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM.
    • Surg Oncol. 2020 Sep;34:40-45. doi: 10.1016/j.suronc.2020.03.001. Epub 2020 Mar 11.
    • Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    • Onstad M, Coleman RL, Westin SN.
    • Drugs. 2020 Aug 27. doi: 10.1007/s40265-020-01382-0. Epub ahead of print.
    • Review
    • Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives.
    • Reverdy T, Sajous C, Péron J, Glehen O, Bakrin N, Gertych W, Lopez J, You B, Freyer G.
    • Cancers (Basel). 2020 Aug 25;12(9):2414. doi: 10.3390/cancers12092414.
    • Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
    • Klotz DM, Wimberger P.
    • Arch Gynecol Obstet. 2020 Aug 24. doi: 10.1007/s00404-020-05677-1. Epub ahead of print.
    • Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    • Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL.
    • J Clin Oncol. 2020 Aug 24:JCO1903107. doi: 10.1200/JCO.19.03107. Epub ahead of print.
    • Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    • Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J.
    • EJC Suppl. 2020 Aug 22;15:1-15. doi: 10.1016/j.ejcsup.2020.02.001.
    • Junshi Biosciences, Impact Therapeutics to Co-Develop PARP Inhibitor Senaparib in China.
    • [No author given]
    • Precision Oncology News. 2020 Aug 20.
    • Breast cancer (BRCA) gene testing in ovarian cancer.
    • Chelariu-Raicu A, Coleman RL.
    • Chin Clin Oncol. 2020 Aug 19:cco-20-4. doi: 10.21037/cco-20-4. Epub ahead of print.
    • LESSONS LEARNED FROM UNDERSTANDING CHEMOTHERAPY RESISTANCE IN EPITHELIAL TUBO-OVARIAN CARCINOMA FROM BRCA1 AND BRCA2 MUTATION CARRIERS.
    • Le Page C, Amuzu S, Rahimi K, Gotlieb W, Ragoussis J, Tonin PN.
    • Semin Cancer Biol. 2020 Aug 19:S1044-579X(20)30177-2. doi: 10.1016/j.semcancer.2020.08.005. Epub ahead of print.
    • Review
    • Study: New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Aug 18.

    Related:

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    • Moving Beyond BRCA - Incorporating Molecular Assays into Ovarian Cancer trials.
    • McMullen M, Karakasis K, Oza AM.
    • Clin Cancer Res. 2020 Aug 14. doi: 10.1158/1078-0432.CCR-20-2429. Epub ahead of print.
    • News
    • A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
    • Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB.
    • Pharmacoeconomics. 2020 Aug 14. doi: 10.1007/s40273-020-00949-9. Epub ahead of print.
    • PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    • Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC.
    • J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924. Epub ahead of print.
    • Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
    • Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M, Attademo L, Arenare L, Spina A, Russo D, Califano D, Losito NS, Setola SV, Franzese E, De Vita F, Orditura M, Pignata S.
    • Int J Gynecol Cancer. 2020 Aug 12:ijgc-2020-001540. doi: 10.1136/ijgc-2020-001540. Epub ahead of print.
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • Front-line ovarian cancer maintenance therapy: PARP inhibitors for all?
    • Berger J.
    • BJOG. 2020 Aug 8. doi: 10.1111/1471-0528.16450. Epub ahead of print.
    • Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    • Pothuri B, O'Cearbhaill R, Eskander R, Armstrong D.
    • Gynecol Oncol. 2020 Aug 7:S0090-8258(20)33747-1. doi: 10.1016/j.ygyno.2020.07.097. Epub ahead of print.
    • Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer.
    • Fabbro M, Colombo PE, Leaha CM, Rouanet P, Carrère S, Quenet F, Gutowski M, Mourregot A, D'Hondt V, Coupier I, Vendrell J, Vilquin P, Pujol P, Solassol J, Mollevi C.
    • Cancers (Basel). 2020 Aug 5;12(8):E2184. doi: 10.3390/cancers12082184.
    • PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.
    • Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang L.
    • Front Oncol. 2020 Aug 4;10:1204. doi: 10.3389/fonc.2020.01204.
    • Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    • Barrington DA, Tubbs C, Smith HJ, Straughn JM Jr, Senter L, Cohn DE.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001550. doi: 10.1136/ijgc-2020-001550. Epub ahead of print.
    • BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.
    • Marchetti C, Minucci A, Pietragalla A, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001670. doi: 10.1136/ijgc-2020-001670. Epub ahead of print.

    Related:

    Guidelines:

    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

    • Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    • DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN.
    • J Clin Oncol. 2020 Aug 4:JCO2000799. doi: 10.1200/JCO.20.00799. Epub ahead of print.
    • Development of new medical treatment for epithelial ovarian cancer recurrence.
    • Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, Bruni S, Vocaturo G, Chiofalo B, Vizza E.
    • Gland Surg. 2020 Aug;9(4):1149-1163. doi: 10.21037/gs-20-413.
    • PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
    • Lee EK, Matulonis UA.
    • Cancers (Basel). 2020 Jul 25;12(8):2054. doi: 10.3390/cancers12082054.
    • Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance.
    • Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ.
    • Cancer Discov. 2020 Jul 22:CD-19-1485. doi: 10.1158/2159-8290.CD-19-1485. Epub ahead of print.
    • The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
    • Dion L, Carton I, Jaillard S, Nyangoh Timoh K, Henno S, Sardain H, Foucher F, Levêque J, de la Motte Rouge T, Brousse S, Lavoué V.
    • J Clin Med. 2020 Jul 15;9(7):E2239. doi: 10.3390/jcm9072239.
    • PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: A meta-analysis.
    • Lin Q, Liu W, Xu S, Shang H, Li J, Guo Y, Tong J.
    • BJOG. 2020 Jul 12. doi: 10.1111/1471-0528.16411. Epub ahead of print.
    • Meta-Analysis
    • First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.
    • Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P.
    • Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874.
    • Update: FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer.
    • [No author given]
    • FORCE. 2020 Jul 7.

    Related:

    Original research:

    Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    • The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
    • Yang Y, Du N, Xie L, Jiang J, Mo J, Hong J, Mao D, Ng DM, Shi H.
    • World J Surg Oncol. 2020 Jul 4;18(1):151. doi: 10.1186/s12957-020-01931-7.
    • Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.
    • Jiang Y, Zhao J, Zhang L, Tian S, Yang T, Wang L, Zhao M, Yang Q, Wang Y, Yang X.
    • Front Oncol. 2020 Jul 3;10:954. doi: 10.3389/fonc.2020.00954.
    • Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
    • Varanda AB, Martins-Logrado A, Ferreira MG, Fior R.
    • Cancers (Basel). 2020 Jul 2;12(7):E1769. doi: 10.3390/cancers12071769.
    • Sequence Now, Later, or Never?
    • Hagemann IS.
    • Clin Chem. 2020 Jul 1;66(7):883-885. doi: 10.1093/clinchem/hvaa053.
    • Case report

    Related:

    Commentary:

    Commentary on Sequence Now, Later, or Never?

    • Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report.
    • Favier L, Truc G, Boidot R, Bengrine-Lefevre L.
    • Mol Clin Oncol. 2020 Jul;13(1):73-75. doi: 10.3892/mco.2020.2035. Epub 2020 Apr 27.
    • The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    • Winship AL, Griffiths M, Lliberos Requesens C, Sarma U, Phillips KA, Hutt KJ.
    • Hum Reprod. 2020 Jun 30:deaa128. doi: 10.1093/humrep/deaa128. Epub ahead of print.
    • Integration of PARP-inhibitors in ovarian cancer therapy.
    • Pietragalla A, Ciccarone F, Nero C, Scambia G, Lorusso D, Daniele G.
    • Explor Target Antitumor Ther. 2020 [Jun 29];1(3):171-182. doi: 10.37349/etat.2020.00011. Epub 2020 Jun 29.
    • DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
    • Tomasova K, Cumova A, Seborova K, Horak J, Koucka K, Vodickova L, Vaclavikova R, Vodicka P.
    • Cancers (Basel). 2020 Jun 28;12(7):E1713. doi: 10.3390/cancers12071713.
    • Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer.
    • Gorodnova TV, Sokolenko AP, Kondratiev SV, Kotiv KB, Belyaev AM, Berlev IV, Imyanitov EN.
    • Invest New Drugs. 2020 Jun 26. doi: 10.1007/s10637-020-00965-8. Epub ahead of print.
    • Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service.
    • Patrizio A, Ludovica B, Giulia F, Claudio J, Nicoletta C, Francesco C.
    • Clin Ther. 2020 Jun 23:S0149-2918(20)30233-2. doi: 10.1016/j.clinthera.2020.04.015. Epub ahead of print.
    • Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    • Lee EK, Matulonis UA.
    • Expert Opin Emerg Drugs. 2020 Jun 22:1-23. doi: 10.1080/14728214.2020.1773791. Epub ahead of print.
    • Review
    • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
    • Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS.
    • J Clin Oncol. 2020 Jun 22:JCO1902404. doi: 10.1200/JCO.19.02404. Epub ahead of print.
    • Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study.
    • Majic A, Miše BP, Matkovic V, Lovasic IB, Katic K, Canjko I, Frobe A, Bajic Z, Vrdoljak E.
    • J Oncol. 2020 Jun 20;2020:6423936. doi: 10.1155/2020/6423936.
    • PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    • Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J.
    • Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0.
    • The forefront of ovarian cancer therapy: update on PARP inhibitors.
    • Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S.
    • Ann Oncol. 2020 Jun 19:S0923-7534(20)39891-4. doi: 10.1016/j.annonc.2020.06.004. Epub ahead of print.
    • Review
    • Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
    • McMullen M, Karakasis K, Madariaga A, Oza AM.
    • Cancers (Basel). 2020 Jun 17;12(6):E1607. doi: 10.3390/cancers12061607.
    • Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
    • Huang XZ, Jia H, Xiao Q, Li RZ, Wang XS, Yin HY, Zhou X.
    • Front Oncol. 2020 Jun 16;10:958. doi: 10.3389/fonc.2020.00958.
    • BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.
    • Liu YL, Selenica P, Zhou Q, Iasonos A, Callahan M, Feit NZ, Boland J, Vazquez-Garcia I, Mandelker D, Zehir A, Burger RA, Powell DJ Jr, Friedman C, Cadoo K, Grisham R, Konner JA, O'Cearbhaill RE, Aghajanian C, Reis-Filho JS, Weigelt B, Zamarin D.
    • JCO Precis Oncol. 2020 Jun 16;4:PO.20.00069. doi: 10.1200/PO.20.00069.
    • Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer.
    • Evangelisti G, Barra F, Moioli M, Sala P, Stigliani S, Gustavino C, Costantini S, Ferrero S.
    • Expert Opin Investig Drugs. 2020 Jun 15. doi: 10.1080/13543784.2020.1783238. Epub ahead of print.
    • Review
    • Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    • Marchetti C, Minucci A, D'Indinosante M, Ergasti R, Arcieri M, Capoluongo ED, Pietragalla A, Caricato C, Scambi G, Fagotti A.
    • Gynecol Oncol. 2020 Jun 15. pii: S0090-8258(20)32294-0. doi: 10.1016/j.ygyno.2020.06.479. Epub ahead of print
    • PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
    • Franzese E, Diana A, Centonze S, Pignata S, De Vita F, Ciardiello F, Orditura M.
    • Front Oncol. 2020 Jun 12;10:782. doi: 10.3389/fonc.2020.00782.
    • Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis.
    • Nahshon C, Barnett-Griness O, Segev Y, Schmidt M, Ostrovsky L, Lavie O.
    • Int J Gynecol Cancer. 2020 Jun 9:ijgc-2020-001392. doi: 10.1136/ijgc-2020-001392. Epub ahead of print.
    • Meta-analysis
    • PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 4.
    • Germline Testing In Advanced Cancer Can Lead to Targeted Tx.
    • Nelson R.
    • Medscape. Conference News. 2020 Jun 2.
    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
    • Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J.
    • Chin J Cancer Res. 2020 Jun;32(3):370-382. doi: 10.21147/j.issn.1000-9604.2020.03.08.
    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Olaparib Makes OS Gains in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2020 May 29. doi: 10.1158/2159-8290.CD-NB2020-048. Epub ahead of print.
    • News
    • High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    • Mazzuccato G, De Bonis M, Carboni V, Marchetti C, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Mol Biol Rep. 2020 May 28. doi: 10.1007/s11033-020-05504-5. Epub ahead of print.
    • Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    • Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F.
    • Int J Mol Sci. 2020 May 27;21(11):E3805. doi: 10.3390/ijms21113805.
    • Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    • Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI.
    • Cancer Treat Rev. 2020 May 26;87:102040. doi: 10.1016/j.ctrv.2020.102040. Epub ahead of print.
    • Review
    • Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer - a potential management strategy in the era of COVID-19.
    • Vetter MH, Smrz SA, Copeland LJ, Cohn DE.
    • Am J Obstet Gynecol. 2020 May 23:S0002-9378(20)30569-X. doi: 10.1016/j.ajog.2020.05.037. Epub ahead of print.
    • EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    • Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan Q, Braunstein M, Karakasis K, Cirlan I, Pedersen S, Li T, Fariñas-Madrid L, Lee YC, Liu ZA, Pugh TJ, Oza AM.
    • Clin Cancer Res. 2020 May 22:clincanres.4121.2019. doi: 10.1158/1078-0432.CCR-19-4121. Epub ahead of print.
    • PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
    • Kurnit KC, Avila M, Hinchcliff E, Coleman RL, Westin SN.
    • Pharmacol Ther. 2020 May 22:107588. doi: 10.1016/j.pharmthera.2020.107588. Epub ahead of print.
    • Review
    • Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
    • Milanesio MC, Giordano S, Valabrega G.
    • Cancers (Basel). 2020 May 21;12(5):E1315. doi: 10.3390/cancers12051315.
    • Wise Management of Ovarian Cancer: On the Cutting Edge.
    • Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • J Pers Med. 2020 May 21;10(2):E41. doi: 10.3390/jpm10020041.
    • New OS Data With Olaparib Support 'New Era' for Ovarian Cancer.
    • Davenport L.
    • Medscape. 2020 May 14.
    • Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
    • Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, Taylor-Harding B, Tanaka H, Orsulic S, Junza A, Yanes O, Muñoz-Pinedo C, Palomero L, Pujana MÀ, Perales JC, Viñals F.
    • EMBO Mol Med. 2020 May 13:e11217. doi: 10.15252/emmm.201911217. Epub ahead of print.
    • Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    • Lampert EJ, Zimmer AS, Padget MR, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri M, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM.
    • Clin Cancer Res. 2020 May 12:clincanres.0056.2020. doi: 10.1158/1078-0432.CCR-20-0056. Epub ahead of print.
    • Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer.
    • Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B.
    • Cancers (Basel). 2020 May 11;12(5):E1206. doi: 10.3390/cancers12051206.
    • FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer.
    • [No author given]
    • GenomeWeb. 2020 May 11.
    • Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    • Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    • J Pathol Clin Res. 2020 May 11. doi: 10.1002/cjp2.168. Epub ahead of print.
    • The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
    • Jacob SL, Kiedrowski LA, Chae YK.
    • Heliyon. 2020 May 8;6(5):e03841. doi: 10.1016/j.heliyon.2020.e03841.
    • Integrating Genetic and Genomic Testing Into Oncology Practice.
    • Domchek SM, Mardis E, Carlisle JW, Owonikoko TK.
    • Am Soc Clin Oncol Educ Book. 2020 May;40:e259-e263. doi: 10.1200/EDBK_280607.
    • A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    • Shi T, Yin S, Zhu J, Zhang P, Liu J, Zhu Y, Wu S, Chen X, Wang X, Teng Y, Zhu T, Yu A, Zhang Y, Feng Y, Huang H, Bao W, Li Y, Jiang W, Zhang P, Li J, Ai Z, Zhang W, Jia H, Zhang Y, Jiang R, Zhang J, Gao W, Luan Y, Zang R.
    • J Gynecol Oncol. 2020 May;31(3):e61. doi: 10.3802/jgo.2020.31.e61.

    Related:

    Addendum:

    Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.

    Identifier: NCT03983226: Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial). (ClinicalTrials.gov)

    • Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    • Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL.
    • Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9.

    Related:

    Commentary, Introductory article:

    Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.

    • GSK Gets Broad Zejula Indication in Ovarian Cancer; FDA Deems Myriad Genetics' Test Complementary
    • [No author given.]
    • GenomeWeb. Business & Policy. 2020 Apr 30.

    Related:

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • FDA approves niraparib for first-line maintenance of advanced ovarian cancer.
    • [No author given.]
    • U.S. Food & Drug Administration. Drug Approvals and Databases. 2020 Apr 29.

    Related:

    Research review: Study: New FDA approval for maintenance therapy in ovarian cancer. (FORCE. XRAYS.)

    • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    • Choucair K, Morand S, Stanbery L, Edelman G, Dworkin L, Nemunaitis J.
    • Cancer Gene Ther. 2020 Apr 28. doi: 10.1038/s41417-020-0174-y. [Epub ahead of print]
    • Review
    • A single nucleotide variant of human PARP1 determines response to PARP inhibitors.
    • Cashman R, Zilberberg A, Priel A, Philip H, Varvak A, Jacob A, Shoval I, Efroni S.
    • NPJ Precis Oncol. 2020 Apr 27;4:10. doi: 10.1038/s41698-020-0113-2. eCollection 2020.
    • Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
    • Lord R, Rauniyar J, Morris T, Condon O, Jones R, Miller R, Hall M, Lofts F, Glasspool RM, Hudson E.
    • Int J Gynecol Cancer. 2020 Apr 21. pii: ijgc-2019-000973. doi: 10.1136/ijgc-2019-000973. [Epub ahead of print]
    • Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    • Gralewska P, Gajek A, Marczak A, Rogalska A.
    • J Hematol Oncol. 2020 Apr 21;13(1):39. doi: 10.1186/s13045-020-00874-6.
    • Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
    • Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA.
    • Cancers (Basel). 2020 Apr 14;12(4). pii: E972. doi: 10.3390/cancers12040972.
    • Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
    • Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G.
    • J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19.
    • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    • Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.
    • J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27.

    Related:

    Commentary:

    BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.

    • Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
    • Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK.
    • Med Oncol. 2020 Apr 10;37(5):48. doi: 10.1007/s12032-020-01371-z.
    • Case report
    • Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
    • Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S.
    • Int J Gynecol Cancer. 2020 Apr 9. pii: ijgc-2020-001288. doi: 10.1136/ijgc-2020-001288. [Epub ahead of print]
    • CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
    • Li J, Zhi X, Chen S, Shen X, Chen C, Yuan L, Guo J, Meng D, Chen M, Yao L.
    • Am J Cancer Res. 2020 Apr 1;10(4):1140-1155. eCollection 2020.
    • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.
    • Cancer Chemother Pharmacol. 2020 Apr;85(4):741-751. doi: 10.1007/s00280-020-04030-2. Epub 2020 Feb 13.
    • Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
    • Choi MC, Hwang S, Kim S, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim TH, Kang H, An HJ.
    • Cancer Res Treat. 2020 Apr;52(2):634-644. doi: 10.4143/crt.2019.207. Epub 2020 Jan 6.
    • Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
    • Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.
    • Oncol Lett. 2020 Apr;19(4):2629-2638. doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31.
    • Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    • Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S.
    • Biosci Rep. 2020 Mar 27;40(3). pii: BSR20192226. doi: 10.1042/BSR20192226.
    • Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    • Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
    • Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
    • Ovarian Cancer Patients in Netherlands To Get 'Tumor-First' BRCA Testing.
    • Anderson A.
    • Precision Oncology News. 2020 Mar 23.
    • News
    • Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series.
    • Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X.
    • J Ovarian Res. 2020 Mar 17;13(1):29. doi: 10.1186/s13048-020-00629-4.
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    • Kerliu L, Myruski S, Bhatti A, Soni P, Petrosius P, Pervanas HC, Horton ER.
    • Ann Pharmacother. 2020 Mar 16:1060028020912749. doi: 10.1177/1060028020912749. [Epub ahead of print]
    • Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.
    • Ibrahim EM, Refae AA, Bayer AM, Sagr ER.
    • Future Oncol. 2020 Mar 13. doi: 10.2217/fon-2020-0057. [Epub ahead of print]
    • Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    • Wolford JE, Bai J, Moore KN, Kristeleit R, Monk BJ, Tewari KS.
    • Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176-1. doi: 10.1016/j.ygyno.2020.02.030. [Epub ahead of print]
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    • Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
    • BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
    • Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    • Liontos M, Sotiropoulou M, Kaparelou M, Tzannis K, Tsironis G, Kyriazoglou A, Tsiara A, Zakopoulou R, Koutsoukos K, Zagouri F, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Bamias A.
    • Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224-9. doi: 10.1016/j.ygyno.2020.03.008. [Epub ahead of print]
    • The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
    • Patel M, Nowsheen S, Maraboyina S, Xia F.
    • Cell Biosci. 2020 Mar 11;10:35. doi: 10.1186/s13578-020-00390-7. eCollection 2020.
    • Prognostic value of radiological recurrence patterns in ovarian cancer.
    • Roze JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, Scholten RJPM, Zweemer RP.
    • Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219-5. doi: 10.1016/j.ygyno.2020.03.003. [Epub ahead of print]
    • Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer.
    • You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M, Liang Z.
    • Front Oncol. 2020 Mar 10;10:295. doi: 10.3389/fonc.2020.00295. eCollection 2020.
    • RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
    • Jones WD, Michener CM, Biscotti C, Braicu I, Sehouli J, Ganapathi MK, Ganapathi RN.
    • Cancers (Basel). 2020 Mar 7;12(3). pii: E620. doi: 10.3390/cancers12030620.
    • Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
    • Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • BMC Cancer. 2020 Mar 4;20(1):185. doi: 10.1186/s12885-020-6688-8.
    • Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
    • Chevalier LM, Billaud A, Fronteau S, Dauvé J, Patsouris A, Verriele V, Morel A.
    • Mol Diagn Ther. 2020 Mar 2. doi: 10.1007/s40291-020-00452-z. [Epub ahead of print]
    • PARP and PARG inhibitors in cancer treatment.
    • Slade D.
    • Genes Dev. 2020 Mar 1;34(5-6):360-394. doi: 10.1101/gad.334516.119. Epub 2020 Feb 6.
    • PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.
    • Konstantinopoulos PA, Lheureux S, Moore KN.
    • Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-16. doi: 10.1200/EDBK_288015.
    • Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
    • Gu L, Du N, Jin Q, Li S, Xie L, Mo J, Shen Z, Mao D, Ji J, Khadaroo PA, Chen B.
    • Crit Rev Oncol Hematol. 2020 Mar;147:102888. doi: 10.1016/j.critrevonc.2020.102888. Epub 2020 Jan 30.
    • Review
    • A profile on the FoundationFocus CDxBRCA tests.
    • Ford L, Wolford JE, Brown SM, Randall LM.
    • Expert Rev Mol Diagn. 2020 Mar;20(3):285-292. doi: 10.1080/14737159.2020.1701438. Epub 2020 Feb 6.
    • Review
    • Therapeutic options for mucinous ovarian carcinoma.
    • Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL.
    • Gynecol Oncol. 2020 Mar;156(3):552-560. doi: 10.1016/j.ygyno.2019.12.015. Epub 2020 Jan 2.
    • SGO Special Topic: PARP Inhibitor Maintenance Therapy after Initial Chemotherapy.
    • Armstrong DK, Eskander R, Cearbhaill R, Pothuri B.
    • Gynecologic Oncology. Podcasts. 2020 Mar.
    • Podcast
    • [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
    • Marom I, Lavie O, Ostrovsky L, Kugelman N, Schmidt M, Segev Y.
    • Harefuah. 2020 Mar;159(3):175-180.
    • Review, [Article in Hebrew]
    • Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
    • Randall M, Burgess K, Buckingham L, Usha L.
    • J Natl Compr Canc Netw. 2020 Mar;18(3):223-228. doi: 10.6004/jnccn.2019.7378.
    • Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
    • Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH.
    • Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702.
    • Review

    Related:

    Editorial:

    Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy.

    Press: Cancer Threat Persists After Risk-Reducing Surgery — Occult tumors, recurrence, new cancers after prophylactic salpingo-oophorectomy. (Medpage Today)

    • Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
    • Carbajal-Mamani SL, Markham MJ, Santolaya-Forgas J, Castagno JC, Cardenas-Goicoechea J.
    • Obstet Gynecol Sci. 2020 Mar;63(2):205-208. doi: 10.5468/ogs.2020.63.2.205. Epub 2020 Feb 5.
    • The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
    • Curtin NJ.
    • Cancers (Basel). 2020 Feb 29;12(3). pii: E564. doi: 10.3390/cancers12030564.
    • Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer.
    • Aust S, Schwameis R, Gagic T, Müllauer L, Langthaler E, Prager G, Grech C, Reinthaller A, Krainer M, Pils D, Grimm C, Polterauer S.
    • Cancers (Basel). 2020 Feb 27;12(3). pii: E548. doi: 10.3390/cancers12030548.
    • Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC.
    • Iavazzo C, Fotiou A, Tsiatas M, Christopoulou A, Spiliotis J, Sugarbaker P.
    • Pleura Peritoneum. 2020 Feb 26;5(1):20190029. doi: 10.1515/pp-2019-0029.
    • Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
    • Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, George A, Krell J.
    • Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.
    • Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.
    • Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM.
    • Diagnostics (Basel). 2020 Feb 22;10(2). pii: E121. doi: 10.3390/diagnostics10020121.
    • PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
    • Lightfoot M, Montemorano L, Bixel K.
    • Curr Oncol Rep. 2020 Feb 17;22(3):29. doi: 10.1007/s11912-020-0873-4.
    • Review
    • Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    • Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N.
    • Sci Rep. 2020 Feb 17;10(1):2757. doi: 10.1038/s41598-020-59671-3.
    • Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    • Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.
    • Cancer Chemother Pharmacol. 2020 Feb 13. doi: 10.1007/s00280-020-04030-2. [Epub ahead of print]
    • Myriad Files sPMA With FDA for Test to ID Best Responders to Lynparza, Avastin Combination.
    • [No author given]
    • GenomeWeb. 2020 Feb 11.
    • Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
    • Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V.
    • Support Care Cancer. 2020 Feb 11. doi: 10.1007/s00520-020-05320-4. [Epub ahead of print]
    • Guidelines
    • PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
    • Min A, Im SA.
    • Cancers (Basel). 2020 Feb 8;12(2). pii: E394. doi: 10.3390/cancers12020394.
    • Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
    • Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.
    • Clin Cancer Res. 2020 Feb 7. pii: clincanres.2933.2019. doi: 10.1158/1078-0432.CCR-19-2933. [Epub ahead of print]
    • Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis.
    • Ricci AD, Rizzo A, Novelli M, Tavolari S, Palloni A, Tober N, Abbati F, Mollica V, DE Lorenzo S, Turchetti D, DI Marco M, Brandi G.
    • Anticancer Res. 2020 Feb;40(2):597-608. doi: 10.21873/anticanres.13989.
    • Review
    • PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
    • Segan L, Beekman A, Parfrey S, Perrin M.
    • Eur Heart J Case Rep. 2019 Dec 31;4(1):1-5. doi: 10.1093/ehjcr/ytz230. eCollection 2020 Feb.
    • Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group.
    • J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080.

    Related:

    Letter:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • PARP inhibitors: a tsunami of indications in different malignancies.
    • Haddad G, Saadé MC, Eid R, Haddad FG, Kourie HR.
    • Pharmacogenomics. 2020 Feb;21(3):221-230. doi: 10.2217/pgs-2019-0113.
    • Review
    • BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
    • Teixeira LA, Candido Dos Reis FJ.
    • Target Oncol. 2020 Feb;15(1):37-46. doi: 10.1007/s11523-020-00697-y.
    • Meta-Analysis

    Related:

    Comment, Letter:

    Comment on: BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.

    Reply, Letter:

    Author's Reply to Jia et al.: "BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis".

    • Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
    • Lieberman HB.
    • Transl Cancer Res. 2020 Feb;9(2):418-420. doi: 10.21037/tcr.2019.12.102.

    Related:

    Original research:

    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

    • Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.
    • Souid S, Aissaoui D, Srairi-Abid N, Essafi-Benkhadir K.
    • Curr Drug Targets. 2020 Jan 28. doi: 10.2174/1389450121666200128161733. [Epub ahead of print]
    • Review
    • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    • Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.
    • J Clin Oncol. 2020 Jan 27:JCO1902960. doi: 10.1200/JCO.19.02960. [Epub ahead of print]
    • Myriad Genetics Seeks Supplemental Approval of HRD Test as CDx for GSK Ovarian Cancer Drug.
    • [No author given]
    • GenomeWeb. 2020 Jan 23.
    • Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    • Havrilesky LJ, Lim S, Ehrisman JA, Lorenzo A, Alvarez Secord A, Yang JC, Johnson FR, Gonzalez JM, Reed SD.
    • Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070-6. doi: 10.1016/j.ygyno.2020.01.026. [Epub ahead of print]
    • A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer: Emerging Treatment Options in Advanced Ovarian Cancer.
    • Alvarez RD, Liu J.
    • National Comprehensive Cancer Network. Continuing Education. 2020 Jan 21.
    • CME Webinar
    • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    • Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M, Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA.
    • Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060-3. doi: 10.1016/j.ygyno.2020.01.018. [Epub ahead of print]
    • Genetic testing for epithelial ovarian cancer.
    • Amin N, Chaabouni N, George A.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Jan 16. pii: S1521-6934(20)30017-1. doi: 10.1016/j.bpobgyn.2020.01.005. [Epub ahead of print]
    • Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    • Bixel K, Vetter M, Davidson B, Berchuck A, Cohn D, Copeland L, Fowler JM, Havrilesky L, Lee PS, O'Malley DM, Salani R, Valea F, Alvarez Secord A, Backes F.
    • Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837-2. doi: 10.1016/j.ygyno.2019.12.016. [Epub ahead of print]
    • Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    • Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H.
    • Biomed Pharmacother. 2020 Jan 10;123:109661. doi: 10.1016/j.biopha.2019.109661. [Epub ahead of print]
    • A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    • Monk BJ, Herzog TJ, Wang G, Triantos S, Maul S, Knoblauch R, McGowan T, Shalaby WSW, Coleman RL.
    • Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873-6. doi: 10.1016/j.ygyno.2019.12.043. [Epub ahead of print]
    • MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1.
    • Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S.
    • J Exp Clin Cancer Res. 2020 Jan 2;39(1):3. doi: 10.1186/s13046-019-1490-7.

Continue to Older References